[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJ_X4TXr2aqCmyPbTchiuGFKJJ7jF7PccucwiIquKl5A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":60,"rows":67},"Bausch & Lomb Incorporated",[4],221,false,12,62,49179,14,100,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Cataract",37,{"name":18,"count":19},"Myopia",34,{"name":21,"count":22},"Astigmatism",15,{"name":24,"count":22},"Inflammation",{"name":26,"count":8},"Allergic Conjunctivitis",{"name":28,"count":29},"Pain",11,{"name":31,"count":32},"Ocular Hypertension",8,{"name":34,"count":32},"Dry Eye",[36,41,46,51,55],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06565650","A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.","2025-11","Miebo",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07168902","Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension","2026-05","BL1107 Low dose",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07128628","A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","2026-11","Lifitegrast\u002FPerfluorohexyloctane Fixed Dose Combination",{"nctId":52,"briefTitle":53,"date":49,"intervention":54},"NCT06978244","A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers","BL1332 ophthalmic solution",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07412496","A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy","2027-02","Topical Ocular BL1332 low dose",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,112,130,375,393,411,429,451,469,487,511,529,547,569,587,678,721,746,771,798,822,840,867,885,909,927,945,963,989,1007,1032,1050,1068,1086,1152,1196,1257,1315,1357,1399,1442,1473,1510,1548,1571,1593,1626,1648,1670,1692,1722,1759,1781,1815,1837,1865,1893,1923,1945,1967,1989,2024,2042,2060,2083,2101,2119,2144,2162,2186,2204,2226,2244,2262,2285,2313,2331,2349,2367,2385,2403,2421,2443,2461,2484,2502,2520,2538,2556,2574,2592,2610,2628,2653,2671,2689,2707,2732,2750,2773,2798,2825,2843,2861,2879,2905,2923,2941,2959,2977,3004,3022,3040,3064,3085,3106,3129,3147,3170,3188,3214,3232,3256,3279,3304,3322,3340,3358,3376,3394,3418,3436,3454,3472,3500,3518,3536,3554,3572,3596,3614,3632,3658,3681,3702,3725,3743,3761,3779,3812,3837],{"intervention":40,"totalTrials":69,"cells":70},3,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":110},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":73},[],{"trials":79,"activeCount":73},[],{"trials":81,"activeCount":109,"soonestReadout":39},[82,92,100],{"nctId":83,"briefTitle":84,"status":85,"phases":86,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":91},"NCT06309953","A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease","COMPLETED",[65],"2024-06-17","2024-02-28",99,[34],[40],{"nctId":37,"briefTitle":38,"status":93,"phases":94,"primaryCompletion":39,"completion":39,"start":95,"enrollment":96,"conditions":97,"interventions":98},"ACTIVE_NOT_RECRUITING",[65],"2024-07-31",216,[34],[40,99],"Saline",{"nctId":101,"briefTitle":102,"status":85,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":108},"NCT06346340","A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry\u002FKeratometry and Postoperative Refractive Accuracy",[65],"2025-02-24","2024-04-30",97,[34],[40],1,{"trials":111,"activeCount":73},[],{"intervention":99,"totalTrials":109,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":128},{"trials":115,"activeCount":73},[],{"trials":117,"activeCount":73},[],{"trials":119,"activeCount":73},[],{"trials":121,"activeCount":73},[],{"trials":123,"activeCount":109,"soonestReadout":39},[124],{"nctId":37,"briefTitle":38,"status":93,"phases":125,"primaryCompletion":39,"completion":39,"start":95,"enrollment":96,"conditions":126,"interventions":127},[65],[34],[40,99],{"trials":129,"activeCount":73},[],{"intervention":131,"totalTrials":132,"cells":133},"Vehicle",21,{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":184,"PHASE4":358,"NA":373},{"trials":135,"activeCount":73},[],{"trials":137,"activeCount":73},[],{"trials":139,"activeCount":109,"soonestReadout":49},[140,151,161,172],{"nctId":141,"briefTitle":142,"status":85,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT00622908","Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis",[63],"2005-06","2004-12",270,[148],"Bacterial Conjunctivitis",[150,131],"ISV-403",{"nctId":47,"briefTitle":48,"status":152,"phases":153,"primaryCompletion":49,"completion":49,"start":154,"enrollment":155,"conditions":156,"interventions":158},"RECRUITING",[63],"2025-10-24",423,[157],"Dry Eye Disease",[50,159,160,131,131,131],"Lifitegrast","Perfluorohexyloctane",{"nctId":162,"briefTitle":163,"status":85,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT01289431","Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis",[63],"2011-04","2011-02",236,[169],"Conjunctivitis, Allergic",[171,131],"Mapracorat",{"nctId":173,"briefTitle":174,"status":175,"phases":176,"primaryCompletion":177,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT00348439","Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment","TERMINATED",[63],"2007-08","2006-04",29,[181],"Vitreoretinal Traction Syndrome",[183,131],"Plasmin",{"trials":185,"activeCount":73},[186,199,209,220,231,242,253,263,274,284,296,305,317,329,340,348],{"nctId":187,"briefTitle":188,"status":85,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT01959230","Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness",[64],"2013-12-20","2013-11-07",60,[194],"Hyperemia",[196,131,197,198],"Brimonidine Tartrate","Sodium Fluorescein","Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP",{"nctId":200,"briefTitle":201,"status":85,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT00347932","A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.",[64],"2007-11","2006-06",957,[207],"Acute Bacterial Conjunctivitis",[150,131],{"nctId":210,"briefTitle":211,"status":175,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT01740388","Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis",[64],"2013-07","2013-11","2013-02",136,[148],[219,131],"Besifloxacin",{"nctId":221,"briefTitle":222,"status":85,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"NCT01996839","Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",[64],"2014-05","2014-07","2013-12",514,[24,28,15],[230,230,131,131],"Loteprednol Etabonate Gel",{"nctId":232,"briefTitle":233,"status":85,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},"NCT03489941","A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle",[64],"2018-04-29","2018-04-07",65,[26],[240,241,131],"EM-100","Zaditor®",{"nctId":243,"briefTitle":244,"status":85,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"NCT01175590","Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle",[64],"2011-12","2012-02","2010-06",518,[148],[252,131],"Besivance",{"nctId":254,"briefTitle":255,"status":85,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT01230125","Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery",[64],"2011-06","2011-08","2010-11",311,[15],[171,131],{"nctId":264,"briefTitle":265,"status":85,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":272},"NCT01159015","Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers",[64],"2010-09","2010-10","2010-07",534,[26],[273,131],"KetoNaph",{"nctId":275,"briefTitle":276,"status":85,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT01959243","Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants",[64],"2014-04-23","2014-06-23","2014-02-22",507,[194],[196,131,197,198],{"nctId":285,"briefTitle":286,"status":85,"phases":287,"primaryCompletion":288,"completion":248,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT00770133","Ketotifen\u002FNaphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.",[64],"2010-04","2010-02",141,[26],[293,294,295,131],"Ketotifen\u002Fnaphazoline","Naphazoline","Ketotifen",{"nctId":297,"briefTitle":298,"status":175,"phases":299,"primaryCompletion":300,"completion":301,"start":166,"enrollment":302,"conditions":303,"interventions":304},"NCT01298752","Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery",[64],"2011-09","2011-11",177,[24,28,15],[171,131],{"nctId":306,"briefTitle":307,"status":85,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT00198536","Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome",[63,64],"2005-12","2005-04",159,[313],"Dry Eye Syndromes",[315,316,131],"Ecabet 2.83%","Ecabet 3.70%",{"nctId":318,"briefTitle":319,"status":85,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT05579730","Evaluation of Brimonidine Tartrate\u002FKetotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis",[64],"2023-07-22","2022-10-12",188,[26],[326,327,328,131],"Brimonidine tartrate 0.025%\u002Fketotifen fumarate 0.035%","Brimonidine Tartrate 0.025%","Ketotifen Fumarate 0.035%",{"nctId":330,"briefTitle":331,"status":85,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT01591655","Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",[64],"2013-09","2013-10","2012-07",360,[15,24,338],"Surgery",[171,131],{"nctId":341,"briefTitle":342,"status":85,"phases":343,"primaryCompletion":268,"completion":166,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT00972777","Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis",[63,64],"2009-10",474,[148],[219,131],{"nctId":349,"briefTitle":350,"status":85,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":357},"NCT00769886","Ketotifen\u002FNaphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.",[64],"2008-12","2009-06","2008-10",144,[26],[293,295,294,131],{"trials":359,"activeCount":73},[360],{"nctId":361,"briefTitle":362,"status":85,"phases":363,"primaryCompletion":364,"completion":353,"start":365,"enrollment":366,"conditions":367,"interventions":370},"NCT00420628","Pediatric Zylet Safety and Efficacy Study",[65],"2009-01","2006-11",108,[368,369],"Chalazion","Hordeolum",[371,372],"loteprednol etabonate\u002Ftobramycin opthalmic suspension","vehicle",{"trials":374,"activeCount":73},[],{"intervention":50,"totalTrials":109,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":378,"activeCount":73},[],{"trials":380,"activeCount":73},[],{"trials":382,"activeCount":109,"soonestReadout":49},[383],{"nctId":47,"briefTitle":48,"status":152,"phases":384,"primaryCompletion":49,"completion":49,"start":154,"enrollment":155,"conditions":385,"interventions":386},[63],[157],[50,159,160,131,131,131],{"trials":388,"activeCount":73},[],{"trials":390,"activeCount":73},[],{"trials":392,"activeCount":73},[],{"intervention":159,"totalTrials":109,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":396,"activeCount":73},[],{"trials":398,"activeCount":73},[],{"trials":400,"activeCount":109,"soonestReadout":49},[401],{"nctId":47,"briefTitle":48,"status":152,"phases":402,"primaryCompletion":49,"completion":49,"start":154,"enrollment":155,"conditions":403,"interventions":404},[63],[157],[50,159,160,131,131,131],{"trials":406,"activeCount":73},[],{"trials":408,"activeCount":73},[],{"trials":410,"activeCount":73},[],{"intervention":160,"totalTrials":109,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":414,"activeCount":73},[],{"trials":416,"activeCount":73},[],{"trials":418,"activeCount":109,"soonestReadout":49},[419],{"nctId":47,"briefTitle":48,"status":152,"phases":420,"primaryCompletion":49,"completion":49,"start":154,"enrollment":155,"conditions":421,"interventions":422},[63],[157],[50,159,160,131,131,131],{"trials":424,"activeCount":73},[],{"trials":426,"activeCount":73},[],{"trials":428,"activeCount":73},[],{"intervention":45,"totalTrials":109,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":432,"activeCount":73},[],{"trials":434,"activeCount":73},[],{"trials":436,"activeCount":109,"soonestReadout":44},[437],{"nctId":42,"briefTitle":43,"status":93,"phases":438,"primaryCompletion":44,"completion":44,"start":154,"enrollment":439,"conditions":440,"interventions":442},[63],252,[441],"Glaucoma",[45,443,444],"BL1107 High dose","Timolol maleate 0.5%",{"trials":446,"activeCount":73},[],{"trials":448,"activeCount":73},[],{"trials":450,"activeCount":73},[],{"intervention":443,"totalTrials":109,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":454,"activeCount":73},[],{"trials":456,"activeCount":73},[],{"trials":458,"activeCount":109,"soonestReadout":44},[459],{"nctId":42,"briefTitle":43,"status":93,"phases":460,"primaryCompletion":44,"completion":44,"start":154,"enrollment":439,"conditions":461,"interventions":462},[63],[441],[45,443,444],{"trials":464,"activeCount":73},[],{"trials":466,"activeCount":73},[],{"trials":468,"activeCount":73},[],{"intervention":444,"totalTrials":109,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":472,"activeCount":73},[],{"trials":474,"activeCount":73},[],{"trials":476,"activeCount":109,"soonestReadout":44},[477],{"nctId":42,"briefTitle":43,"status":93,"phases":478,"primaryCompletion":44,"completion":44,"start":154,"enrollment":439,"conditions":479,"interventions":480},[63],[441],[45,443,444],{"trials":482,"activeCount":73},[],{"trials":484,"activeCount":73},[],{"trials":486,"activeCount":73},[],{"intervention":59,"totalTrials":109,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":490,"activeCount":73},[],{"trials":492,"activeCount":73},[],{"trials":494,"activeCount":109,"soonestReadout":58},[495],{"nctId":56,"briefTitle":57,"status":496,"phases":497,"primaryCompletion":58,"completion":58,"start":498,"enrollment":499,"conditions":500,"interventions":502},"NOT_YET_RECRUITING",[63],"2026-04",123,[501],"Pain, Postoperative",[59,503,504],"Topical Ocular BL1332 high dose","BL1332 Vehicle ophthalmic vehicle",{"trials":506,"activeCount":73},[],{"trials":508,"activeCount":73},[],{"trials":510,"activeCount":73},[],{"intervention":503,"totalTrials":109,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":514,"activeCount":73},[],{"trials":516,"activeCount":73},[],{"trials":518,"activeCount":109,"soonestReadout":58},[519],{"nctId":56,"briefTitle":57,"status":496,"phases":520,"primaryCompletion":58,"completion":58,"start":498,"enrollment":499,"conditions":521,"interventions":522},[63],[501],[59,503,504],{"trials":524,"activeCount":73},[],{"trials":526,"activeCount":73},[],{"trials":528,"activeCount":73},[],{"intervention":504,"totalTrials":109,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":532,"activeCount":73},[],{"trials":534,"activeCount":73},[],{"trials":536,"activeCount":109,"soonestReadout":58},[537],{"nctId":56,"briefTitle":57,"status":496,"phases":538,"primaryCompletion":58,"completion":58,"start":498,"enrollment":499,"conditions":539,"interventions":540},[63],[501],[59,503,504],{"trials":542,"activeCount":73},[],{"trials":544,"activeCount":73},[],{"trials":546,"activeCount":73},[],{"intervention":54,"totalTrials":109,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":550,"activeCount":73},[],{"trials":552,"activeCount":109,"soonestReadout":49},[553],{"nctId":52,"briefTitle":53,"status":93,"phases":554,"primaryCompletion":49,"completion":49,"start":555,"enrollment":556,"conditions":557,"interventions":559},[62],"2025-07-29",24,[558],"Ocular Pain",[54,560],"BL1332 ophthalmic vehicle",{"trials":562,"activeCount":73},[],{"trials":564,"activeCount":73},[],{"trials":566,"activeCount":73},[],{"trials":568,"activeCount":73},[],{"intervention":560,"totalTrials":109,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":572,"activeCount":73},[],{"trials":574,"activeCount":109,"soonestReadout":49},[575],{"nctId":52,"briefTitle":53,"status":93,"phases":576,"primaryCompletion":49,"completion":49,"start":555,"enrollment":556,"conditions":577,"interventions":578},[62],[558],[54,560],{"trials":580,"activeCount":73},[],{"trials":582,"activeCount":73},[],{"trials":584,"activeCount":73},[],{"trials":586,"activeCount":73},[],{"intervention":588,"totalTrials":589,"cells":590},"Loteprednol Etabonate",7,{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":604,"PHASE3":606,"PHASE4":648,"NA":676},{"trials":592,"activeCount":73},[],{"trials":594,"activeCount":73},[595],{"nctId":596,"briefTitle":597,"status":85,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":22,"conditions":601,"interventions":603},"NCT03098953","Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations",[62],"2017-05-12","2017-04-10",[602],"Healthy",[588],{"trials":605,"activeCount":73},[],{"trials":607,"activeCount":73},[608,619,629,641],{"nctId":609,"briefTitle":610,"status":85,"phases":611,"primaryCompletion":612,"completion":353,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT00699153","Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery",[64],"2009-05","2008-06",400,[616],"Ocular Inflammation",[588,618],"Vehicle of Ophthalmic Loteprednol Etabonate",{"nctId":620,"briefTitle":621,"status":85,"phases":622,"primaryCompletion":248,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":627},"NCT01010633","Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery",[64],"2010-08","2009-11",406,[24,28],[628,588],"Vehicle of Loteprednol Etabonate",{"nctId":630,"briefTitle":631,"status":85,"phases":632,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":638},"NCT01475643","Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.",[64],"2017-06-02","2017-07","2013-06",107,[15],[639,640],"Loteprednol etabonate","Prednisolones acetate",{"nctId":642,"briefTitle":643,"status":85,"phases":644,"primaryCompletion":267,"completion":268,"start":289,"enrollment":645,"conditions":646,"interventions":647},"NCT01060072","Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery",[64],407,[24,28],[639,628],{"trials":649,"activeCount":73},[650,664],{"nctId":651,"briefTitle":652,"status":85,"phases":653,"primaryCompletion":654,"completion":655,"start":613,"enrollment":656,"conditions":657,"interventions":659},"NCT00705159","Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis",[65],"2010-03","2010-05",137,[658],"Conjunctivitis",[660,661,662,663],"loteprednol etabonate and tobramycin","loteprednol etabonate","Tobramycin","Vehicle of Zylet",{"nctId":665,"briefTitle":666,"status":85,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":674},"NCT01437982","A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%",[65],"2015-10-19","2010-08-05",140,[672,673,24],"Conjunctivitis, Seasonal Allergic","Conjunctivitis, Giant Papillary",[588,675],"Prednisolone Acetate 1% Oph Susp",{"trials":677,"activeCount":73},[],{"intervention":679,"totalTrials":69,"cells":680},"Latanoprostene bunod",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":693,"PHASE3":695,"PHASE4":707,"NA":719},{"trials":682,"activeCount":73},[],{"trials":684,"activeCount":73},[685],{"nctId":686,"briefTitle":687,"status":85,"phases":688,"primaryCompletion":689,"completion":334,"start":213,"enrollment":556,"conditions":690,"interventions":692},"NCT01895985","Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers",[62],"2013-08",[691],"Intraocular Pressure",[679],{"trials":694,"activeCount":73},[],{"trials":696,"activeCount":73},[697],{"nctId":698,"briefTitle":699,"status":85,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":706},"NCT01895972","Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT",[64],"2015-04-02","2015-04-14","2013-07-05",130,[441,31],[679],{"trials":708,"activeCount":73},[709],{"nctId":710,"briefTitle":711,"status":712,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":73,"conditions":716,"interventions":717},"NCT04140279","A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension","WITHDRAWN",[65],"2023-08","2022-05-13",[31],[718],"Latanoprostene Bunod",{"trials":720,"activeCount":73},[],{"intervention":722,"totalTrials":109,"cells":723},"instillation of NOV03",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":732,"NA":744},{"trials":725,"activeCount":73},[],{"trials":727,"activeCount":73},[],{"trials":729,"activeCount":73},[],{"trials":731,"activeCount":73},[],{"trials":733,"activeCount":73},[734],{"nctId":735,"briefTitle":736,"status":85,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT05723770","Effects of NOV03 on the Tear Film",[65],"2023-12-23","2023-08-14",33,[742],"Dry Eye Disease (DED)",[722],{"trials":745,"activeCount":73},[],{"intervention":747,"totalTrials":109,"cells":748},"Vitrase (ovine hyaluronidase) Lyophilized",{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":755,"PHASE4":757,"NA":769},{"trials":750,"activeCount":73},[],{"trials":752,"activeCount":73},[],{"trials":754,"activeCount":73},[],{"trials":756,"activeCount":73},[],{"trials":758,"activeCount":73},[759],{"nctId":760,"briefTitle":761,"status":85,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":768},"NCT00198549","Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics",[65],"2005-01","2005-03","2004-09",40,[28],[747],{"trials":770,"activeCount":73},[],{"intervention":772,"totalTrials":109,"cells":773},"pegaptanib sodium",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":782,"NA":796},{"trials":775,"activeCount":73},[],{"trials":777,"activeCount":73},[],{"trials":779,"activeCount":73},[],{"trials":781,"activeCount":73},[],{"trials":783,"activeCount":73},[784],{"nctId":785,"briefTitle":786,"status":85,"phases":787,"primaryCompletion":788,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":795},"NCT01573572","Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium",[65],"2019-11-14","2010-04-22",131,[792,793,794],"Age-Related Macular Degeneration","Retinal Vein Occlusion","Diabetic Macular Edema",[772],{"trials":797,"activeCount":73},[],{"intervention":799,"totalTrials":109,"cells":800},"Loteprednol etabonate 0.5% and tobramycin 0.3%",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":820},{"trials":802,"activeCount":73},[],{"trials":804,"activeCount":73},[],{"trials":806,"activeCount":73},[],{"trials":808,"activeCount":73},[],{"trials":810,"activeCount":73},[811],{"nctId":812,"briefTitle":813,"status":85,"phases":814,"primaryCompletion":310,"completion":144,"start":815,"enrollment":816,"conditions":817,"interventions":818},"NCT00532961","Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex",[65],"2005-02",310,[24],[799,819],"Dexamethasone 0.1% and tobramycin 0.3%",{"trials":821,"activeCount":73},[],{"intervention":819,"totalTrials":109,"cells":823},{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":830,"PHASE4":832,"NA":838},{"trials":825,"activeCount":73},[],{"trials":827,"activeCount":73},[],{"trials":829,"activeCount":73},[],{"trials":831,"activeCount":73},[],{"trials":833,"activeCount":73},[834],{"nctId":812,"briefTitle":813,"status":85,"phases":835,"primaryCompletion":310,"completion":144,"start":815,"enrollment":816,"conditions":836,"interventions":837},[65],[24],[799,819],{"trials":839,"activeCount":73},[],{"intervention":841,"totalTrials":109,"cells":842},"Omeprazole 40 mg",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":865},{"trials":844,"activeCount":73},[],{"trials":846,"activeCount":73},[],{"trials":848,"activeCount":73},[],{"trials":850,"activeCount":73},[],{"trials":852,"activeCount":73},[853],{"nctId":854,"briefTitle":855,"status":85,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":863},"NCT02394340","Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris",[65],"2015-04-01","2015-02-03",20,[861,862],"Tinea Pedis","Tinea Cruris",[841,864],"Luliconazole Cream 1%",{"trials":866,"activeCount":73},[],{"intervention":864,"totalTrials":109,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":883},{"trials":870,"activeCount":73},[],{"trials":872,"activeCount":73},[],{"trials":874,"activeCount":73},[],{"trials":876,"activeCount":73},[],{"trials":878,"activeCount":73},[879],{"nctId":854,"briefTitle":855,"status":85,"phases":880,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":881,"interventions":882},[65],[861,862],[841,864],{"trials":884,"activeCount":73},[],{"intervention":886,"totalTrials":109,"cells":887},"Perfluorohexyloctane ophthalmic solution",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":907},{"trials":889,"activeCount":73},[],{"trials":891,"activeCount":73},[],{"trials":893,"activeCount":73},[],{"trials":895,"activeCount":73},[],{"trials":897,"activeCount":73},[898],{"nctId":899,"briefTitle":900,"status":85,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":906},"NCT07054606","A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear",[65],"2025-11-03","2025-07-02",104,[34],[886],{"trials":908,"activeCount":73},[],{"intervention":660,"totalTrials":109,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":925},{"trials":912,"activeCount":73},[],{"trials":914,"activeCount":73},[],{"trials":916,"activeCount":73},[],{"trials":918,"activeCount":73},[],{"trials":920,"activeCount":73},[921],{"nctId":651,"briefTitle":652,"status":85,"phases":922,"primaryCompletion":654,"completion":655,"start":613,"enrollment":656,"conditions":923,"interventions":924},[65],[658],[660,661,662,663],{"trials":926,"activeCount":73},[],{"intervention":662,"totalTrials":109,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":943},{"trials":930,"activeCount":73},[],{"trials":932,"activeCount":73},[],{"trials":934,"activeCount":73},[],{"trials":936,"activeCount":73},[],{"trials":938,"activeCount":73},[939],{"nctId":651,"briefTitle":652,"status":85,"phases":940,"primaryCompletion":654,"completion":655,"start":613,"enrollment":656,"conditions":941,"interventions":942},[65],[658],[660,661,662,663],{"trials":944,"activeCount":73},[],{"intervention":663,"totalTrials":109,"cells":946},{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":961},{"trials":948,"activeCount":73},[],{"trials":950,"activeCount":73},[],{"trials":952,"activeCount":73},[],{"trials":954,"activeCount":73},[],{"trials":956,"activeCount":73},[957],{"nctId":651,"briefTitle":652,"status":85,"phases":958,"primaryCompletion":654,"completion":655,"start":613,"enrollment":656,"conditions":959,"interventions":960},[65],[658],[660,661,662,663],{"trials":962,"activeCount":73},[],{"intervention":964,"totalTrials":109,"cells":965},"Loteprednol etabonate and tobramycin ophthalmic suspension",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":987},{"trials":967,"activeCount":73},[],{"trials":969,"activeCount":73},[],{"trials":971,"activeCount":73},[],{"trials":973,"activeCount":73},[],{"trials":975,"activeCount":73},[976],{"nctId":977,"briefTitle":978,"status":85,"phases":979,"primaryCompletion":980,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":985},"NCT00447577","Zylet vs TobraDex in Blepharokeratoconjunctivitis",[65],"2007-06","2007-01",276,[984],"Blepharokeratoconjunctivitis",[964,986],"Tobramycin and dexamethasone ophthalmic suspension",{"trials":988,"activeCount":73},[],{"intervention":986,"totalTrials":109,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":999,"NA":1005},{"trials":992,"activeCount":73},[],{"trials":994,"activeCount":73},[],{"trials":996,"activeCount":73},[],{"trials":998,"activeCount":73},[],{"trials":1000,"activeCount":73},[1001],{"nctId":977,"briefTitle":978,"status":85,"phases":1002,"primaryCompletion":980,"completion":980,"start":981,"enrollment":982,"conditions":1003,"interventions":1004},[65],[984],[964,986],{"trials":1006,"activeCount":73},[],{"intervention":1008,"totalTrials":109,"cells":1009},"Indomethacin ophthalmic solution",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1018,"NA":1030},{"trials":1011,"activeCount":73},[],{"trials":1013,"activeCount":73},[],{"trials":1015,"activeCount":73},[],{"trials":1017,"activeCount":73},[],{"trials":1019,"activeCount":73},[1020],{"nctId":1021,"briefTitle":1022,"status":85,"phases":1023,"primaryCompletion":353,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1028},"NCT00904904","Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery",[65],"2009-09","2008-04",120,[15,24],[1008,1029],"Ketorolac Ophthalmic Solution",{"trials":1031,"activeCount":73},[],{"intervention":1029,"totalTrials":109,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1042,"NA":1048},{"trials":1035,"activeCount":73},[],{"trials":1037,"activeCount":73},[],{"trials":1039,"activeCount":73},[],{"trials":1041,"activeCount":73},[],{"trials":1043,"activeCount":73},[1044],{"nctId":1021,"briefTitle":1022,"status":85,"phases":1045,"primaryCompletion":353,"completion":1024,"start":1025,"enrollment":1026,"conditions":1046,"interventions":1047},[65],[15,24],[1008,1029],{"trials":1049,"activeCount":73},[],{"intervention":675,"totalTrials":109,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1066},{"trials":1053,"activeCount":73},[],{"trials":1055,"activeCount":73},[],{"trials":1057,"activeCount":73},[],{"trials":1059,"activeCount":73},[],{"trials":1061,"activeCount":73},[1062],{"nctId":665,"briefTitle":666,"status":85,"phases":1063,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":1064,"interventions":1065},[65],[672,673,24],[588,675],{"trials":1067,"activeCount":73},[],{"intervention":371,"totalTrials":109,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1084},{"trials":1071,"activeCount":73},[],{"trials":1073,"activeCount":73},[],{"trials":1075,"activeCount":73},[],{"trials":1077,"activeCount":73},[],{"trials":1079,"activeCount":73},[1080],{"nctId":361,"briefTitle":362,"status":85,"phases":1081,"primaryCompletion":364,"completion":353,"start":365,"enrollment":366,"conditions":1082,"interventions":1083},[65],[368,369],[371,372],{"trials":1085,"activeCount":73},[],{"intervention":1087,"totalTrials":1088,"cells":1089},"Vitrase",6,{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1108,"PHASE3":1120,"PHASE4":1148,"NA":1150},{"trials":1091,"activeCount":73},[],{"trials":1093,"activeCount":73},[1094,1102],{"nctId":1095,"briefTitle":1096,"status":85,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1098,"enrollment":237,"conditions":1099,"interventions":1101},"NCT00198419","Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)",[62],"2004-03",[1100],"Drug Hypersensitivity",[1087],{"nctId":1103,"briefTitle":1096,"status":85,"phases":1104,"primaryCompletion":1105,"completion":765,"start":1105,"enrollment":237,"conditions":1106,"interventions":1107},"NCT00198458",[62],"2004-07",[1100],[1087],{"trials":1109,"activeCount":73},[1110],{"nctId":1111,"briefTitle":1112,"status":85,"phases":1113,"primaryCompletion":365,"completion":365,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1119},"NCT00198471","Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment",[63],"2005-07",10,[1117,1118],"Vitreous Detachment","Diabetic Retinopathy",[1087],{"trials":1121,"activeCount":73},[1122,1129,1140],{"nctId":1123,"briefTitle":1124,"status":85,"phases":1125,"primaryCompletion":145,"completion":815,"start":1126,"enrollment":366,"conditions":1127,"interventions":1128},"NCT00198484","Evaluation of Vitrase as a Spreading Agent",[64],"2004-10",[28],[1087],{"nctId":1130,"briefTitle":1131,"status":85,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT00198510","Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage",[64],"2001-09","2003-03","1998-11",750,[1138,1118],"Vitreous Hemorrhage",[1087,1087,1087],{"nctId":1141,"briefTitle":1131,"status":85,"phases":1142,"primaryCompletion":1133,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1147},"NCT00198497",[64],"2003-06","1999-06",510,[1138,1118],[1087,1087],{"trials":1149,"activeCount":73},[],{"trials":1151,"activeCount":73},[],{"intervention":171,"totalTrials":1088,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1166,"PHASE3":1172,"PHASE4":1192,"NA":1194},{"trials":1155,"activeCount":73},[],{"trials":1157,"activeCount":73},[1158],{"nctId":1159,"briefTitle":1160,"status":85,"phases":1161,"primaryCompletion":213,"completion":213,"start":215,"enrollment":1162,"conditions":1163,"interventions":1165},"NCT01736462","Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days",[62],61,[1164],"Corneal Endothelial Cell Changes",[171],{"trials":1167,"activeCount":73},[1168],{"nctId":162,"briefTitle":163,"status":85,"phases":1169,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":1170,"interventions":1171},[63],[169],[171,131],{"trials":1173,"activeCount":73},[1174,1180,1184,1188],{"nctId":1175,"briefTitle":331,"status":85,"phases":1176,"primaryCompletion":635,"completion":213,"start":335,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT01591161",[64],369,[15,24,338],[171],{"nctId":254,"briefTitle":255,"status":85,"phases":1181,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":1182,"interventions":1183},[64],[15],[171,131],{"nctId":297,"briefTitle":298,"status":175,"phases":1185,"primaryCompletion":300,"completion":301,"start":166,"enrollment":302,"conditions":1186,"interventions":1187},[64],[24,28,15],[171,131],{"nctId":330,"briefTitle":331,"status":85,"phases":1189,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":1190,"interventions":1191},[64],[15,24,338],[171,131],{"trials":1193,"activeCount":73},[],{"trials":1195,"activeCount":73},[],{"intervention":1197,"totalTrials":1198,"cells":1199},"bromfenac ophthalmic solution",5,{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1216,"PHASE4":1253,"NA":1255},{"trials":1201,"activeCount":73},[],{"trials":1203,"activeCount":73},[],{"trials":1205,"activeCount":73},[1206],{"nctId":1207,"briefTitle":1208,"status":85,"phases":1209,"primaryCompletion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1215},"NCT00585975","Efficacy and Safety of Bromfenac Ophthalmic Solution",[63],"2008-07","2007-10",568,[1214],"Cataract Surgery",[1197],{"trials":1217,"activeCount":73},[1218,1226,1236,1244],{"nctId":1219,"briefTitle":1220,"status":85,"phases":1221,"primaryCompletion":1222,"start":613,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT00703781","Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery",[64],"2008-11",126,[15],[1197],{"nctId":1227,"briefTitle":1228,"status":85,"phases":1229,"primaryCompletion":1230,"completion":246,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1234},"NCT01367249","Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery",[64],"2011-07","2011-05",440,[28,24,15],[1235],"Bromfenac Ophthalmic Solution",{"nctId":1237,"briefTitle":1238,"status":85,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":204,"enrollment":1241,"conditions":1242,"interventions":1243},"NCT00333918","Safety\u002FEfficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery",[64],"2007-03",522,[28,24],[1197],{"nctId":1245,"briefTitle":1246,"status":85,"phases":1247,"primaryCompletion":1024,"completion":1248,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1252},"NCT00853970","Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery",[64],"2009-12","2009-02",299,[28,24],[1235],{"trials":1254,"activeCount":73},[],{"trials":1256,"activeCount":73},[],{"intervention":1258,"totalTrials":1259,"cells":1260},"BOL-303259-X",4,{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1289,"PHASE4":1311,"NA":1313},{"trials":1262,"activeCount":73},[],{"trials":1264,"activeCount":73},[],{"trials":1266,"activeCount":73},[1267,1278],{"nctId":1268,"briefTitle":1269,"status":85,"phases":1270,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1276},"NCT01223378","Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension",[63],"2011-12-20","2012-06-22","2010-12-13",413,[691],[1258,1277],"Latanoprost",{"nctId":1279,"briefTitle":1280,"status":85,"phases":1281,"primaryCompletion":226,"completion":1282,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1287},"NCT01707381","BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension",[63],"2014-02","2012-11",25,[31,1286],"Open Angle Glaucoma",[1258,1288],"Timolol maleate",{"trials":1290,"activeCount":73},[1291,1303],{"nctId":1292,"briefTitle":1293,"status":85,"phases":1294,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT01749904","Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension",[64],"2015-06-02","2015-09-30","2013-01-31",420,[1300,31],"Open-Angle Glaucoma",[1258,1302,1258],"Timolol",{"nctId":1304,"briefTitle":1305,"status":85,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1298,"conditions":1309,"interventions":1310},"NCT01749930","Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension",[64],"2015-05","2013-01",[1300,31],[1258,1302,1258],{"trials":1312,"activeCount":73},[],{"trials":1314,"activeCount":73},[],{"intervention":219,"totalTrials":1259,"cells":1316},{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1332,"PHASE3":1334,"PHASE4":1353,"NA":1355},{"trials":1318,"activeCount":73},[],{"trials":1320,"activeCount":73},[1321],{"nctId":1322,"briefTitle":1323,"status":85,"phases":1324,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1329},"NCT00905762","Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation",[62],"2009-04","2009-03",119,[602],[1330,1331,219],"Gatifloxacin","Moxifloxacin",{"trials":1333,"activeCount":73},[],{"trials":1335,"activeCount":73},[1336,1345,1349],{"nctId":1337,"briefTitle":1338,"status":85,"phases":1339,"primaryCompletion":1340,"completion":1340,"start":204,"enrollment":1341,"conditions":1342,"interventions":1343},"NCT00348348","A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis",[64],"2007-07",1161,[207],[219,1344],"Moxifloxacin solution",{"nctId":210,"briefTitle":211,"status":175,"phases":1346,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":1347,"interventions":1348},[64],[148],[219,131],{"nctId":341,"briefTitle":342,"status":85,"phases":1350,"primaryCompletion":268,"completion":166,"start":344,"enrollment":345,"conditions":1351,"interventions":1352},[63,64],[148],[219,131],{"trials":1354,"activeCount":73},[],{"trials":1356,"activeCount":73},[],{"intervention":628,"totalTrials":1259,"cells":1358},{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1385,"PHASE4":1395,"NA":1397},{"trials":1360,"activeCount":73},[],{"trials":1362,"activeCount":73},[],{"trials":1364,"activeCount":73},[1365,1375],{"nctId":1366,"briefTitle":1367,"status":85,"phases":1368,"primaryCompletion":655,"completion":623,"start":288,"enrollment":1369,"conditions":1370,"interventions":1371},"NCT01107405","Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge",[63],101,[26],[1372,1372,1372,1373,1374],"Loteprednol etabonate base","Loteprednol etabonate suspension","Vehicle of loteprednol etabonate",{"nctId":1376,"briefTitle":1377,"status":85,"phases":1378,"primaryCompletion":1379,"completion":1379,"start":1380,"enrollment":1327,"conditions":1381,"interventions":1382},"NCT00560638","Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye",[63],"2006-02","2005-11",[34],[1383,1383,1384],"loteprednol etabonate ophthalmic suspension, 0.5%","vehicle of loteprednol etabonate",{"trials":1386,"activeCount":73},[1387,1391],{"nctId":620,"briefTitle":621,"status":85,"phases":1388,"primaryCompletion":248,"completion":623,"start":624,"enrollment":625,"conditions":1389,"interventions":1390},[64],[24,28],[628,588],{"nctId":642,"briefTitle":643,"status":85,"phases":1392,"primaryCompletion":267,"completion":268,"start":289,"enrollment":645,"conditions":1393,"interventions":1394},[64],[24,28],[639,628],{"trials":1396,"activeCount":73},[],{"trials":1398,"activeCount":73},[],{"intervention":1400,"totalTrials":69,"cells":1401},"NOV03",{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1406,"PHASE3":1408,"PHASE4":1438,"NA":1440},{"trials":1403,"activeCount":73},[],{"trials":1405,"activeCount":73},[],{"trials":1407,"activeCount":73},[],{"trials":1409,"activeCount":73},[1410,1420,1429],{"nctId":1411,"briefTitle":1412,"status":85,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1418},"NCT04567329","Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)",[64],"2021-08-30","2020-11-18",620,[157],[1400,1419],"Saline Solution",{"nctId":1421,"briefTitle":1422,"status":85,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1428},"NCT04140227","Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)",[64],"2022-01-05","2020-09-24",256,[742],[1400],{"nctId":1430,"briefTitle":1431,"status":85,"phases":1432,"primaryCompletion":1433,"completion":1433,"start":1434,"enrollment":1435,"conditions":1436,"interventions":1437},"NCT04139798","Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)",[64],"2021-03-12","2020-07-20",599,[742],[1400],{"trials":1439,"activeCount":73},[],{"trials":1441,"activeCount":73},[],{"intervention":196,"totalTrials":69,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1457,"PHASE3":1459,"PHASE4":1469,"NA":1471},{"trials":1445,"activeCount":73},[],{"trials":1447,"activeCount":73},[1448],{"nctId":1449,"briefTitle":1450,"status":85,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1282,"enrollment":8,"conditions":1454,"interventions":1455},"NCT02039765","Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.",[62],"2014-03","2014-04",[194],[1456],"Brimonidine tartrate",{"trials":1458,"activeCount":73},[],{"trials":1460,"activeCount":73},[1461,1465],{"nctId":187,"briefTitle":188,"status":85,"phases":1462,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":1463,"interventions":1464},[64],[194],[196,131,197,198],{"nctId":275,"briefTitle":276,"status":85,"phases":1466,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":1467,"interventions":1468},[64],[194],[196,131,197,198],{"trials":1470,"activeCount":73},[],{"trials":1472,"activeCount":73},[],{"intervention":1330,"totalTrials":69,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1496,"PHASE3":1498,"PHASE4":1506,"NA":1508},{"trials":1476,"activeCount":73},[],{"trials":1478,"activeCount":73},[1479,1483],{"nctId":1322,"briefTitle":1323,"status":85,"phases":1480,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":1481,"interventions":1482},[62],[602],[1330,1331,219],{"nctId":1484,"briefTitle":1485,"status":85,"phases":1486,"primaryCompletion":1487,"completion":1488,"start":1249,"enrollment":1489,"conditions":1490,"interventions":1492},"NCT00824070","Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects",[62],"2009-07","2009-08",105,[1491],"Cataract Extraction",[1493,1494,1495],"Besifloxacin hydrochloride","moxifloxacin hydrochloride","gatifloxacin",{"trials":1497,"activeCount":73},[],{"trials":1499,"activeCount":73},[1500],{"nctId":1501,"briefTitle":1502,"status":175,"phases":1503,"primaryCompletion":1308,"completion":334,"start":1231,"enrollment":740,"conditions":1504,"interventions":1505},"NCT01330355","Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis",[64],[148],[252,1330],{"trials":1507,"activeCount":73},[],{"trials":1509,"activeCount":73},[],{"intervention":1511,"totalTrials":69,"cells":1512},"Bromfenac",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1544,"NA":1546},{"trials":1514,"activeCount":73},[],{"trials":1516,"activeCount":73},[],{"trials":1518,"activeCount":73},[],{"trials":1520,"activeCount":73},[1521,1527,1537],{"nctId":1522,"briefTitle":1220,"status":85,"phases":1523,"primaryCompletion":364,"completion":1248,"start":613,"enrollment":1524,"conditions":1525,"interventions":1526},"NCT00704418",[64],156,[15],[1511],{"nctId":1528,"briefTitle":1529,"status":85,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1536},"NCT00198445","Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery",[64],"2004-01","2003-05",527,[1535,15],"Postoperative Complications",[1511],{"nctId":1538,"briefTitle":1539,"status":85,"phases":1540,"primaryCompletion":177,"completion":177,"start":365,"enrollment":1541,"conditions":1542,"interventions":1543},"NCT00423007","Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis",[64],90,[26],[1511],{"trials":1545,"activeCount":73},[],{"trials":1547,"activeCount":73},[],{"intervention":150,"totalTrials":1549,"cells":1550},2,{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1561,"PHASE4":1567,"NA":1569},{"trials":1552,"activeCount":73},[],{"trials":1554,"activeCount":73},[],{"trials":1556,"activeCount":73},[1557],{"nctId":141,"briefTitle":142,"status":85,"phases":1558,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":1559,"interventions":1560},[63],[148],[150,131],{"trials":1562,"activeCount":73},[1563],{"nctId":200,"briefTitle":201,"status":85,"phases":1564,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":1565,"interventions":1566},[64],[207],[150,131],{"trials":1568,"activeCount":73},[],{"trials":1570,"activeCount":73},[],{"intervention":1302,"totalTrials":1549,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1589,"NA":1591},{"trials":1574,"activeCount":73},[],{"trials":1576,"activeCount":73},[],{"trials":1578,"activeCount":73},[],{"trials":1580,"activeCount":73},[1581,1585],{"nctId":1292,"briefTitle":1293,"status":85,"phases":1582,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1583,"interventions":1584},[64],[1300,31],[1258,1302,1258],{"nctId":1304,"briefTitle":1305,"status":85,"phases":1586,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1298,"conditions":1587,"interventions":1588},[64],[1300,31],[1258,1302,1258],{"trials":1590,"activeCount":73},[],{"trials":1592,"activeCount":73},[],{"intervention":1594,"totalTrials":1549,"cells":1595},"T-PRED",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1612,"PHASE4":1622,"NA":1624},{"trials":1597,"activeCount":73},[],{"trials":1599,"activeCount":73},[],{"trials":1601,"activeCount":73},[1602],{"nctId":1603,"briefTitle":1604,"status":85,"phases":1605,"primaryCompletion":1606,"completion":1606,"start":1607,"enrollment":1608,"conditions":1609,"interventions":1610},"NCT00699803","Study of T-PRED(TM) Compared to Pred Forte(R)",[63],"2008-08","2008-05",64,[15],[1594,1611],"Pred Forte",{"trials":1613,"activeCount":73},[1614],{"nctId":1615,"briefTitle":1616,"status":85,"phases":1617,"primaryCompletion":1488,"completion":1488,"start":1249,"enrollment":1618,"conditions":1619,"interventions":1620},"NCT00854061","Study of T-PRED(TM) Compared to Pred Forte(R) II",[64],172,[15],[1621,1611],"T-Pred",{"trials":1623,"activeCount":73},[],{"trials":1625,"activeCount":73},[],{"intervention":1611,"totalTrials":1549,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1638,"PHASE4":1644,"NA":1646},{"trials":1629,"activeCount":73},[],{"trials":1631,"activeCount":73},[],{"trials":1633,"activeCount":73},[1634],{"nctId":1603,"briefTitle":1604,"status":85,"phases":1635,"primaryCompletion":1606,"completion":1606,"start":1607,"enrollment":1608,"conditions":1636,"interventions":1637},[63],[15],[1594,1611],{"trials":1639,"activeCount":73},[1640],{"nctId":1615,"briefTitle":1616,"status":85,"phases":1641,"primaryCompletion":1488,"completion":1488,"start":1249,"enrollment":1618,"conditions":1642,"interventions":1643},[64],[15],[1621,1611],{"trials":1645,"activeCount":73},[],{"trials":1647,"activeCount":73},[],{"intervention":197,"totalTrials":1549,"cells":1649},{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1666,"NA":1668},{"trials":1651,"activeCount":73},[],{"trials":1653,"activeCount":73},[],{"trials":1655,"activeCount":73},[],{"trials":1657,"activeCount":73},[1658,1662],{"nctId":187,"briefTitle":188,"status":85,"phases":1659,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":1660,"interventions":1661},[64],[194],[196,131,197,198],{"nctId":275,"briefTitle":276,"status":85,"phases":1663,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":1664,"interventions":1665},[64],[194],[196,131,197,198],{"trials":1667,"activeCount":73},[],{"trials":1669,"activeCount":73},[],{"intervention":198,"totalTrials":1549,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1678,"PHASE4":1688,"NA":1690},{"trials":1673,"activeCount":73},[],{"trials":1675,"activeCount":73},[],{"trials":1677,"activeCount":73},[],{"trials":1679,"activeCount":73},[1680,1684],{"nctId":187,"briefTitle":188,"status":85,"phases":1681,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":1682,"interventions":1683},[64],[194],[196,131,197,198],{"nctId":275,"briefTitle":276,"status":85,"phases":1685,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":1686,"interventions":1687},[64],[194],[196,131,197,198],{"trials":1689,"activeCount":73},[],{"trials":1691,"activeCount":73},[],{"intervention":1693,"totalTrials":1549,"cells":1694},"Bepreve",{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1701,"PHASE4":1718,"NA":1720},{"trials":1696,"activeCount":73},[],{"trials":1698,"activeCount":73},[],{"trials":1700,"activeCount":73},[],{"trials":1702,"activeCount":73},[1703,1710],{"nctId":1704,"briefTitle":1705,"status":85,"phases":1706,"primaryCompletion":1607,"start":1211,"enrollment":1707,"conditions":1708,"interventions":1709},"NCT00586625","Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers",[64],861,[26],[1693],{"nctId":1711,"briefTitle":1712,"status":85,"phases":1713,"primaryCompletion":1340,"start":1714,"enrollment":636,"conditions":1715,"interventions":1716},"NCT00424398","Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis",[63,64],"2007-02",[169],[1693,1717],"Bepotastine Besilate",{"trials":1719,"activeCount":73},[],{"trials":1721,"activeCount":73},[],{"intervention":1723,"totalTrials":1549,"cells":1724},"Fluocinolone Acetonide 2.1mg",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1755,"NA":1757},{"trials":1726,"activeCount":73},[],{"trials":1728,"activeCount":73},[],{"trials":1730,"activeCount":73},[],{"trials":1732,"activeCount":73},[1733,1743],{"nctId":1734,"briefTitle":1735,"status":175,"phases":1736,"primaryCompletion":178,"completion":178,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1741},"NCT00456482","Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant",[63,64],"2002-05",239,[1740],"Non-infectious Uveitis",[1742,1723],"Fluocinolone Acetonide 0.59mg",{"nctId":1744,"briefTitle":1745,"status":85,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":1749,"conditions":1750,"interventions":1752},"NCT00407082","Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants",[63,64],"2005-09","2000-12",278,[1751],"Noninfectious Posterior Uveitis",[1753,1754],"fluocinolone acetonide intravitreal implant","Fluocinolone acetonide 2.1mg",{"trials":1756,"activeCount":73},[],{"trials":1758,"activeCount":73},[],{"intervention":252,"totalTrials":1549,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1777,"NA":1779},{"trials":1762,"activeCount":73},[],{"trials":1764,"activeCount":73},[],{"trials":1766,"activeCount":73},[],{"trials":1768,"activeCount":73},[1769,1773],{"nctId":1501,"briefTitle":1502,"status":175,"phases":1770,"primaryCompletion":1308,"completion":334,"start":1231,"enrollment":740,"conditions":1771,"interventions":1772},[64],[148],[252,1330],{"nctId":243,"briefTitle":244,"status":85,"phases":1774,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":1775,"interventions":1776},[64],[148],[252,131],{"trials":1778,"activeCount":73},[],{"trials":1780,"activeCount":73},[],{"intervention":1782,"totalTrials":1549,"cells":1783},"brinzolamide 1% ophthalmic suspension",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1801,"PHASE4":1811,"NA":1813},{"trials":1785,"activeCount":73},[],{"trials":1787,"activeCount":73},[],{"trials":1789,"activeCount":73},[1790],{"nctId":1791,"briefTitle":1792,"status":85,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1799},"NCT03896633","Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt",[62,63],"2018-11-17","2018-02-28",637,[441,1798],"Open Angle or Ocular Hypertension",[1782,1800],"Azopt 1%",{"trials":1802,"activeCount":73},[1803],{"nctId":1804,"briefTitle":1792,"status":85,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1808,"conditions":1809,"interventions":1810},"NCT01722604",[64],"2012-09","2012-01",258,[441,1798],[1782,1800],{"trials":1812,"activeCount":73},[],{"trials":1814,"activeCount":73},[],{"intervention":1800,"totalTrials":1549,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1827,"PHASE4":1833,"NA":1835},{"trials":1818,"activeCount":73},[],{"trials":1820,"activeCount":73},[],{"trials":1822,"activeCount":73},[1823],{"nctId":1791,"briefTitle":1792,"status":85,"phases":1824,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":1825,"interventions":1826},[62,63],[441,1798],[1782,1800],{"trials":1828,"activeCount":73},[1829],{"nctId":1804,"briefTitle":1792,"status":85,"phases":1830,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1808,"conditions":1831,"interventions":1832},[64],[441,1798],[1782,1800],{"trials":1834,"activeCount":73},[],{"trials":1836,"activeCount":73},[],{"intervention":1838,"totalTrials":1549,"cells":1839},"Bepotastine besilate",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1855,"PHASE4":1861,"NA":1863},{"trials":1841,"activeCount":73},[],{"trials":1843,"activeCount":73},[],{"trials":1845,"activeCount":73},[1846],{"nctId":1847,"briefTitle":1848,"status":85,"phases":1849,"primaryCompletion":215,"completion":1850,"start":1308,"enrollment":1851,"conditions":1852,"interventions":1854},"NCT01753739","Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)",[63],"2013-05",617,[1853],"Seasonal Allergic Rhinitis",[1838],{"trials":1856,"activeCount":73},[1857],{"nctId":1711,"briefTitle":1712,"status":85,"phases":1858,"primaryCompletion":1340,"start":1714,"enrollment":636,"conditions":1859,"interventions":1860},[63,64],[169],[1693,1717],{"trials":1862,"activeCount":73},[],{"trials":1864,"activeCount":73},[],{"intervention":230,"totalTrials":1549,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1889,"NA":1891},{"trials":1868,"activeCount":73},[],{"trials":1870,"activeCount":73},[],{"trials":1872,"activeCount":73},[],{"trials":1874,"activeCount":73},[1875,1885],{"nctId":1876,"briefTitle":1877,"status":85,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1883},"NCT02208297","Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",[64],"2015-03","2014-09",326,[24,28,15],[230,1884],"Vehicle Gel",{"nctId":221,"briefTitle":222,"status":85,"phases":1886,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":1887,"interventions":1888},[64],[24,28,15],[230,230,131,131],{"trials":1890,"activeCount":73},[],{"trials":1892,"activeCount":73},[],{"intervention":1884,"totalTrials":1549,"cells":1894},{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1919,"NA":1921},{"trials":1896,"activeCount":73},[],{"trials":1898,"activeCount":73},[],{"trials":1900,"activeCount":73},[],{"trials":1902,"activeCount":73},[1903,1907],{"nctId":1876,"briefTitle":1877,"status":85,"phases":1904,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1905,"interventions":1906},[64],[24,28,15],[230,1884],{"nctId":1908,"briefTitle":1909,"status":85,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1916},"NCT02786901","LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",[64],"2017-06-13","2017-07-01","2016-06",600,[15,28,616],[1917,1918,1884],"Loteprednol Etabonate Ophthalmic Gel dosed TID","Loteprednol Etabonate Ophthalmic Gel dosed BID",{"trials":1920,"activeCount":73},[],{"trials":1922,"activeCount":73},[],{"intervention":293,"totalTrials":1549,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1941,"NA":1943},{"trials":1926,"activeCount":73},[],{"trials":1928,"activeCount":73},[],{"trials":1930,"activeCount":73},[],{"trials":1932,"activeCount":73},[1933,1937],{"nctId":285,"briefTitle":286,"status":85,"phases":1934,"primaryCompletion":288,"completion":248,"start":289,"enrollment":290,"conditions":1935,"interventions":1936},[64],[26],[293,294,295,131],{"nctId":349,"briefTitle":350,"status":85,"phases":1938,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":1939,"interventions":1940},[64],[26],[293,295,294,131],{"trials":1942,"activeCount":73},[],{"trials":1944,"activeCount":73},[],{"intervention":294,"totalTrials":1549,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1963,"NA":1965},{"trials":1948,"activeCount":73},[],{"trials":1950,"activeCount":73},[],{"trials":1952,"activeCount":73},[],{"trials":1954,"activeCount":73},[1955,1959],{"nctId":285,"briefTitle":286,"status":85,"phases":1956,"primaryCompletion":288,"completion":248,"start":289,"enrollment":290,"conditions":1957,"interventions":1958},[64],[26],[293,294,295,131],{"nctId":349,"briefTitle":350,"status":85,"phases":1960,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":1961,"interventions":1962},[64],[26],[293,295,294,131],{"trials":1964,"activeCount":73},[],{"trials":1966,"activeCount":73},[],{"intervention":295,"totalTrials":1549,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1985,"NA":1987},{"trials":1970,"activeCount":73},[],{"trials":1972,"activeCount":73},[],{"trials":1974,"activeCount":73},[],{"trials":1976,"activeCount":73},[1977,1981],{"nctId":285,"briefTitle":286,"status":85,"phases":1978,"primaryCompletion":288,"completion":248,"start":289,"enrollment":290,"conditions":1979,"interventions":1980},[64],[26],[293,294,295,131],{"nctId":349,"briefTitle":350,"status":85,"phases":1982,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":1983,"interventions":1984},[64],[26],[293,295,294,131],{"trials":1986,"activeCount":73},[],{"trials":1988,"activeCount":73},[],{"intervention":1990,"totalTrials":1549,"cells":1991},"Lumify®",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":1998,"PHASE4":2020,"NA":2022},{"trials":1993,"activeCount":73},[],{"trials":1995,"activeCount":73},[],{"trials":1997,"activeCount":73},[],{"trials":1999,"activeCount":73},[2000,2011],{"nctId":2001,"briefTitle":2002,"status":85,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":2006,"conditions":2007,"interventions":2009},"NCT06803654","A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness",[64],"2025-06-29","2025-05-22",578,[2008],"Ocular Redness",[2010,1990],"BTOS-HA",{"nctId":2012,"briefTitle":2013,"status":85,"phases":2014,"primaryCompletion":2015,"completion":2015,"start":715,"enrollment":2016,"conditions":2017,"interventions":2018},"NCT05360784","\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"",[64],"2022-11-23",380,[2008],[2019,1990],"Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation",{"trials":2021,"activeCount":73},[],{"trials":2023,"activeCount":73},[],{"intervention":1419,"totalTrials":109,"cells":2025},{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2038,"NA":2040},{"trials":2027,"activeCount":73},[],{"trials":2029,"activeCount":73},[],{"trials":2031,"activeCount":73},[],{"trials":2033,"activeCount":73},[2034],{"nctId":1411,"briefTitle":1412,"status":85,"phases":2035,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":2036,"interventions":2037},[64],[157],[1400,1419],{"trials":2039,"activeCount":73},[],{"trials":2041,"activeCount":73},[],{"intervention":618,"totalTrials":109,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2056,"NA":2058},{"trials":2045,"activeCount":73},[],{"trials":2047,"activeCount":73},[],{"trials":2049,"activeCount":73},[],{"trials":2051,"activeCount":73},[2052],{"nctId":609,"briefTitle":610,"status":85,"phases":2053,"primaryCompletion":612,"completion":353,"start":613,"enrollment":614,"conditions":2054,"interventions":2055},[64],[616],[588,618],{"trials":2057,"activeCount":73},[],{"trials":2059,"activeCount":73},[],{"intervention":2061,"totalTrials":109,"cells":2062},"0.5% Loteprednol Etabonate Ophthalmic Ointment",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2079,"NA":2081},{"trials":2064,"activeCount":73},[],{"trials":2066,"activeCount":73},[],{"trials":2068,"activeCount":73},[],{"trials":2070,"activeCount":73},[2071],{"nctId":2072,"briefTitle":2073,"status":85,"phases":2074,"primaryCompletion":1326,"completion":1326,"start":2075,"enrollment":614,"conditions":2076,"interventions":2077},"NCT00645671","Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery",[64],"2008-03",[616],[2061,2078],"Vehicle of Loteprednol Etabonate Ophthalmic Ointment",{"trials":2080,"activeCount":73},[],{"trials":2082,"activeCount":73},[],{"intervention":2078,"totalTrials":109,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2097,"NA":2099},{"trials":2086,"activeCount":73},[],{"trials":2088,"activeCount":73},[],{"trials":2090,"activeCount":73},[],{"trials":2092,"activeCount":73},[2093],{"nctId":2072,"briefTitle":2073,"status":85,"phases":2094,"primaryCompletion":1326,"completion":1326,"start":2075,"enrollment":614,"conditions":2095,"interventions":2096},[64],[616],[2061,2078],{"trials":2098,"activeCount":73},[],{"trials":2100,"activeCount":73},[],{"intervention":1742,"totalTrials":109,"cells":2102},{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2109,"PHASE4":2115,"NA":2117},{"trials":2104,"activeCount":73},[],{"trials":2106,"activeCount":73},[],{"trials":2108,"activeCount":73},[],{"trials":2110,"activeCount":73},[2111],{"nctId":1734,"briefTitle":1735,"status":175,"phases":2112,"primaryCompletion":178,"completion":178,"start":1737,"enrollment":1738,"conditions":2113,"interventions":2114},[63,64],[1740],[1742,1723],{"trials":2116,"activeCount":73},[],{"trials":2118,"activeCount":73},[],{"intervention":2120,"totalTrials":109,"cells":2121},"Loteprednol and tobramycin",{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2140,"NA":2142},{"trials":2123,"activeCount":73},[],{"trials":2125,"activeCount":73},[],{"trials":2127,"activeCount":73},[],{"trials":2129,"activeCount":73},[2130],{"nctId":2131,"briefTitle":2132,"status":85,"phases":2133,"primaryCompletion":289,"completion":654,"start":344,"enrollment":2134,"conditions":2135,"interventions":2138},"NCT01028027","Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis",[64],357,[658,2136,2137],"Keratitis","Blepharitis",[2120,2139],"Tobramycin and dexamethasone",{"trials":2141,"activeCount":73},[],{"trials":2143,"activeCount":73},[],{"intervention":2139,"totalTrials":109,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2158,"NA":2160},{"trials":2147,"activeCount":73},[],{"trials":2149,"activeCount":73},[],{"trials":2151,"activeCount":73},[],{"trials":2153,"activeCount":73},[2154],{"nctId":2131,"briefTitle":2132,"status":85,"phases":2155,"primaryCompletion":289,"completion":654,"start":344,"enrollment":2134,"conditions":2156,"interventions":2157},[64],[658,2136,2137],[2120,2139],{"trials":2159,"activeCount":73},[],{"trials":2161,"activeCount":73},[],{"intervention":2163,"totalTrials":109,"cells":2164},"Bromfenac Ophthalmic Solution A",{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2171,"PHASE4":2182,"NA":2184},{"trials":2166,"activeCount":73},[],{"trials":2168,"activeCount":73},[],{"trials":2170,"activeCount":73},[],{"trials":2172,"activeCount":73},[2173],{"nctId":2174,"briefTitle":2175,"status":85,"phases":2176,"primaryCompletion":258,"completion":246,"start":267,"enrollment":2177,"conditions":2178,"interventions":2180},"NCT01212471","A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease",[64],840,[2179],"Dry Eye Syndrome",[2163,2181],"Bromfenac Ophthalmic Solution B",{"trials":2183,"activeCount":73},[],{"trials":2185,"activeCount":73},[],{"intervention":2181,"totalTrials":109,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":73},[],{"trials":2191,"activeCount":73},[],{"trials":2193,"activeCount":73},[],{"trials":2195,"activeCount":73},[2196],{"nctId":2174,"briefTitle":2175,"status":85,"phases":2197,"primaryCompletion":258,"completion":246,"start":267,"enrollment":2177,"conditions":2198,"interventions":2199},[64],[2179],[2163,2181],{"trials":2201,"activeCount":73},[],{"trials":2203,"activeCount":73},[],{"intervention":2205,"totalTrials":109,"cells":2206},"Bepreve (bepotastine besilate ophthalmic solution) 1.5%",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2222,"NA":2224},{"trials":2208,"activeCount":73},[],{"trials":2210,"activeCount":73},[],{"trials":2212,"activeCount":73},[],{"trials":2214,"activeCount":73},[2215],{"nctId":2216,"briefTitle":2217,"status":85,"phases":2218,"primaryCompletion":613,"completion":613,"start":1211,"enrollment":704,"conditions":2219,"interventions":2220},"NCT00586664","Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis",[64],[26],[2205,2221],"Bepotastine Besilate Ophthalmic Solution 1.0%",{"trials":2223,"activeCount":73},[],{"trials":2225,"activeCount":73},[],{"intervention":2221,"totalTrials":109,"cells":2227},{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2240,"NA":2242},{"trials":2229,"activeCount":73},[],{"trials":2231,"activeCount":73},[],{"trials":2233,"activeCount":73},[],{"trials":2235,"activeCount":73},[2236],{"nctId":2216,"briefTitle":2217,"status":85,"phases":2237,"primaryCompletion":613,"completion":613,"start":1211,"enrollment":704,"conditions":2238,"interventions":2239},[64],[26],[2205,2221],{"trials":2241,"activeCount":73},[],{"trials":2243,"activeCount":73},[],{"intervention":1344,"totalTrials":109,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2258,"NA":2260},{"trials":2247,"activeCount":73},[],{"trials":2249,"activeCount":73},[],{"trials":2251,"activeCount":73},[],{"trials":2253,"activeCount":73},[2254],{"nctId":1337,"briefTitle":1338,"status":85,"phases":2255,"primaryCompletion":1340,"completion":1340,"start":204,"enrollment":1341,"conditions":2256,"interventions":2257},[64],[207],[219,1344],{"trials":2259,"activeCount":73},[],{"trials":2261,"activeCount":73},[],{"intervention":2263,"totalTrials":109,"cells":2264},"Lifitegrast\u002Fperfluorohexyloctane",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2281,"NA":2283},{"trials":2266,"activeCount":73},[],{"trials":2268,"activeCount":73},[],{"trials":2270,"activeCount":73},[],{"trials":2272,"activeCount":73},[2273],{"nctId":2274,"briefTitle":2275,"status":712,"phases":2276,"primaryCompletion":2277,"completion":2277,"start":2278,"enrollment":73,"conditions":2279,"interventions":2280},"NCT07111013","A Study to Assess the Long-Term Safety of Lifitegrast\u002FPerfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease",[64],"2027-04","2025-12",[157],[2263],{"trials":2282,"activeCount":73},[],{"trials":2284,"activeCount":73},[],{"intervention":2286,"totalTrials":109,"cells":2287},"Brimonidine Tartrate 0.025%\u002F Ketotifen Fumarate 0.035% Ophthalmic Solution",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2309,"NA":2311},{"trials":2289,"activeCount":73},[],{"trials":2291,"activeCount":73},[],{"trials":2293,"activeCount":73},[],{"trials":2295,"activeCount":73},[2296],{"nctId":2297,"briefTitle":2298,"status":85,"phases":2299,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2305},"NCT05591755","Evaluation of Brimonidine Tartrate\u002FKetotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis",[64],"2023-08-09","2022-11-18",229,[2304],"Seasonal Allergic Conjunctivitis",[2286,2306,2307,2308],"Ketotifen fumarate ophthalmic solution 0.035%","Brimonidine tartrate ophthalmic solution 0.025%","Experimental: Vehicle ophthalmic solution",{"trials":2310,"activeCount":73},[],{"trials":2312,"activeCount":73},[],{"intervention":2306,"totalTrials":109,"cells":2314},{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2327,"NA":2329},{"trials":2316,"activeCount":73},[],{"trials":2318,"activeCount":73},[],{"trials":2320,"activeCount":73},[],{"trials":2322,"activeCount":73},[2323],{"nctId":2297,"briefTitle":2298,"status":85,"phases":2324,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":2302,"conditions":2325,"interventions":2326},[64],[2304],[2286,2306,2307,2308],{"trials":2328,"activeCount":73},[],{"trials":2330,"activeCount":73},[],{"intervention":2307,"totalTrials":109,"cells":2332},{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2345,"NA":2347},{"trials":2334,"activeCount":73},[],{"trials":2336,"activeCount":73},[],{"trials":2338,"activeCount":73},[],{"trials":2340,"activeCount":73},[2341],{"nctId":2297,"briefTitle":2298,"status":85,"phases":2342,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":2302,"conditions":2343,"interventions":2344},[64],[2304],[2286,2306,2307,2308],{"trials":2346,"activeCount":73},[],{"trials":2348,"activeCount":73},[],{"intervention":2308,"totalTrials":109,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":73},[],{"trials":2354,"activeCount":73},[],{"trials":2356,"activeCount":73},[],{"trials":2358,"activeCount":73},[2359],{"nctId":2297,"briefTitle":2298,"status":85,"phases":2360,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":2302,"conditions":2361,"interventions":2362},[64],[2304],[2286,2306,2307,2308],{"trials":2364,"activeCount":73},[],{"trials":2366,"activeCount":73},[],{"intervention":240,"totalTrials":109,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":73},[],{"trials":2372,"activeCount":73},[],{"trials":2374,"activeCount":73},[],{"trials":2376,"activeCount":73},[2377],{"nctId":232,"briefTitle":233,"status":85,"phases":2378,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":2379,"interventions":2380},[64],[26],[240,241,131],{"trials":2382,"activeCount":73},[],{"trials":2384,"activeCount":73},[],{"intervention":241,"totalTrials":109,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":73},[],{"trials":2390,"activeCount":73},[],{"trials":2392,"activeCount":73},[],{"trials":2394,"activeCount":73},[2395],{"nctId":232,"briefTitle":233,"status":85,"phases":2396,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":2397,"interventions":2398},[64],[26],[240,241,131],{"trials":2400,"activeCount":73},[],{"trials":2402,"activeCount":73},[],{"intervention":273,"totalTrials":109,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2411,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":73},[],{"trials":2408,"activeCount":73},[],{"trials":2410,"activeCount":73},[],{"trials":2412,"activeCount":73},[2413],{"nctId":264,"briefTitle":265,"status":85,"phases":2414,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":2415,"interventions":2416},[64],[26],[273,131],{"trials":2418,"activeCount":73},[],{"trials":2420,"activeCount":73},[],{"intervention":2422,"totalTrials":109,"cells":2423},"corticosteroids and immunosuppressants",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2439,"NA":2441},{"trials":2425,"activeCount":73},[],{"trials":2427,"activeCount":73},[],{"trials":2429,"activeCount":73},[],{"trials":2431,"activeCount":73},[2432],{"nctId":2433,"briefTitle":2434,"status":85,"phases":2435,"primaryCompletion":204,"completion":204,"start":2436,"enrollment":670,"conditions":2437,"interventions":2438},"NCT00468871","Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy",[63,64],"2002-04",[1740],[1753,2422],{"trials":2440,"activeCount":73},[],{"trials":2442,"activeCount":73},[],{"intervention":2010,"totalTrials":109,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2457,"NA":2459},{"trials":2446,"activeCount":73},[],{"trials":2448,"activeCount":73},[],{"trials":2450,"activeCount":73},[],{"trials":2452,"activeCount":73},[2453],{"nctId":2001,"briefTitle":2002,"status":85,"phases":2454,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":2006,"conditions":2455,"interventions":2456},[64],[2008],[2010,1990],{"trials":2458,"activeCount":73},[],{"trials":2460,"activeCount":73},[],{"intervention":2462,"totalTrials":109,"cells":2463},"Loteprednol etabonate 0.2%",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2480,"NA":2482},{"trials":2465,"activeCount":73},[],{"trials":2467,"activeCount":73},[],{"trials":2469,"activeCount":73},[],{"trials":2471,"activeCount":73},[2472],{"nctId":2473,"briefTitle":2474,"status":85,"phases":2475,"primaryCompletion":165,"completion":1231,"start":623,"enrollment":2476,"conditions":2477,"interventions":2478},"NCT01435460","Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)",[64],300,[2304],[2462,2479],"Olopatadine 0.1%",{"trials":2481,"activeCount":73},[],{"trials":2483,"activeCount":73},[],{"intervention":2479,"totalTrials":109,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2492,"PHASE4":2498,"NA":2500},{"trials":2487,"activeCount":73},[],{"trials":2489,"activeCount":73},[],{"trials":2491,"activeCount":73},[],{"trials":2493,"activeCount":73},[2494],{"nctId":2473,"briefTitle":2474,"status":85,"phases":2495,"primaryCompletion":165,"completion":1231,"start":623,"enrollment":2476,"conditions":2496,"interventions":2497},[64],[2304],[2462,2479],{"trials":2499,"activeCount":73},[],{"trials":2501,"activeCount":73},[],{"intervention":2019,"totalTrials":109,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2510,"PHASE4":2516,"NA":2518},{"trials":2505,"activeCount":73},[],{"trials":2507,"activeCount":73},[],{"trials":2509,"activeCount":73},[],{"trials":2511,"activeCount":73},[2512],{"nctId":2012,"briefTitle":2013,"status":85,"phases":2513,"primaryCompletion":2015,"completion":2015,"start":715,"enrollment":2016,"conditions":2514,"interventions":2515},[64],[2008],[2019,1990],{"trials":2517,"activeCount":73},[],{"trials":2519,"activeCount":73},[],{"intervention":315,"totalTrials":109,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2534,"NA":2536},{"trials":2523,"activeCount":73},[],{"trials":2525,"activeCount":73},[],{"trials":2527,"activeCount":73},[],{"trials":2529,"activeCount":73},[2530],{"nctId":306,"briefTitle":307,"status":85,"phases":2531,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":2532,"interventions":2533},[63,64],[313],[315,316,131],{"trials":2535,"activeCount":73},[],{"trials":2537,"activeCount":73},[],{"intervention":316,"totalTrials":109,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2552,"NA":2554},{"trials":2541,"activeCount":73},[],{"trials":2543,"activeCount":73},[],{"trials":2545,"activeCount":73},[],{"trials":2547,"activeCount":73},[2548],{"nctId":306,"briefTitle":307,"status":85,"phases":2549,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":2550,"interventions":2551},[63,64],[313],[315,316,131],{"trials":2553,"activeCount":73},[],{"trials":2555,"activeCount":73},[],{"intervention":326,"totalTrials":109,"cells":2557},{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2564,"PHASE4":2570,"NA":2572},{"trials":2559,"activeCount":73},[],{"trials":2561,"activeCount":73},[],{"trials":2563,"activeCount":73},[],{"trials":2565,"activeCount":73},[2566],{"nctId":318,"briefTitle":319,"status":85,"phases":2567,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":2568,"interventions":2569},[64],[26],[326,327,328,131],{"trials":2571,"activeCount":73},[],{"trials":2573,"activeCount":73},[],{"intervention":327,"totalTrials":109,"cells":2575},{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2588,"NA":2590},{"trials":2577,"activeCount":73},[],{"trials":2579,"activeCount":73},[],{"trials":2581,"activeCount":73},[],{"trials":2583,"activeCount":73},[2584],{"nctId":318,"briefTitle":319,"status":85,"phases":2585,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":2586,"interventions":2587},[64],[26],[326,327,328,131],{"trials":2589,"activeCount":73},[],{"trials":2591,"activeCount":73},[],{"intervention":328,"totalTrials":109,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2606,"NA":2608},{"trials":2595,"activeCount":73},[],{"trials":2597,"activeCount":73},[],{"trials":2599,"activeCount":73},[],{"trials":2601,"activeCount":73},[2602],{"nctId":318,"briefTitle":319,"status":85,"phases":2603,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":2604,"interventions":2605},[64],[26],[326,327,328,131],{"trials":2607,"activeCount":73},[],{"trials":2609,"activeCount":73},[],{"intervention":640,"totalTrials":109,"cells":2611},{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2616,"PHASE3":2618,"PHASE4":2624,"NA":2626},{"trials":2613,"activeCount":73},[],{"trials":2615,"activeCount":73},[],{"trials":2617,"activeCount":73},[],{"trials":2619,"activeCount":73},[2620],{"nctId":630,"briefTitle":631,"status":85,"phases":2621,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":2622,"interventions":2623},[64],[15],[639,640],{"trials":2625,"activeCount":73},[],{"trials":2627,"activeCount":73},[],{"intervention":2629,"totalTrials":109,"cells":2630},"Brimonidine Tartrate 0.025%\u002FKetotifen Fumarate 0.035% Ophthalmic Solution",{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2637,"PHASE4":2649,"NA":2651},{"trials":2632,"activeCount":73},[],{"trials":2634,"activeCount":73},[],{"trials":2636,"activeCount":73},[],{"trials":2638,"activeCount":73},[2639],{"nctId":2640,"briefTitle":2641,"status":85,"phases":2642,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":2645,"conditions":2646,"interventions":2647},"NCT05815758","Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%\u002FKetotifen Fumarate 0.035% Combination Ophthalmic Solution",[64],"2023-09-18","2023-04-20",512,[26],[2629,2648],"Vehicle of brimonidine tartrate 0.025%\u002Fketotifen fumarate 0.035% ophthalmic solution",{"trials":2650,"activeCount":73},[],{"trials":2652,"activeCount":73},[],{"intervention":2648,"totalTrials":109,"cells":2654},{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2667,"NA":2669},{"trials":2656,"activeCount":73},[],{"trials":2658,"activeCount":73},[],{"trials":2660,"activeCount":73},[],{"trials":2662,"activeCount":73},[2663],{"nctId":2640,"briefTitle":2641,"status":85,"phases":2664,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":2645,"conditions":2665,"interventions":2666},[64],[26],[2629,2648],{"trials":2668,"activeCount":73},[],{"trials":2670,"activeCount":73},[],{"intervention":1917,"totalTrials":109,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2685,"NA":2687},{"trials":2674,"activeCount":73},[],{"trials":2676,"activeCount":73},[],{"trials":2678,"activeCount":73},[],{"trials":2680,"activeCount":73},[2681],{"nctId":1908,"briefTitle":1909,"status":85,"phases":2682,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":2683,"interventions":2684},[64],[15,28,616],[1917,1918,1884],{"trials":2686,"activeCount":73},[],{"trials":2688,"activeCount":73},[],{"intervention":1918,"totalTrials":109,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2703,"NA":2705},{"trials":2692,"activeCount":73},[],{"trials":2694,"activeCount":73},[],{"trials":2696,"activeCount":73},[],{"trials":2698,"activeCount":73},[2699],{"nctId":1908,"briefTitle":1909,"status":85,"phases":2700,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":2701,"interventions":2702},[64],[15,28,616],[1917,1918,1884],{"trials":2704,"activeCount":73},[],{"trials":2706,"activeCount":73},[],{"intervention":2708,"totalTrials":109,"cells":2709},"Prednisolone and Tobramycin",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2716,"PHASE4":2728,"NA":2730},{"trials":2711,"activeCount":73},[],{"trials":2713,"activeCount":73},[],{"trials":2715,"activeCount":73},[],{"trials":2717,"activeCount":73},[2718],{"nctId":2719,"briefTitle":2720,"status":85,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":1114,"enrollment":2723,"conditions":2724,"interventions":2726},"NCT00198523","A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte",[64],"2005-10",132,[2725,1535],"Eye Infections",[2708,2727],"Prednisolone",{"trials":2729,"activeCount":73},[],{"trials":2731,"activeCount":73},[],{"intervention":2727,"totalTrials":109,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2746,"NA":2748},{"trials":2735,"activeCount":73},[],{"trials":2737,"activeCount":73},[],{"trials":2739,"activeCount":73},[],{"trials":2741,"activeCount":73},[2742],{"nctId":2719,"briefTitle":2720,"status":85,"phases":2743,"primaryCompletion":2722,"completion":2722,"start":1114,"enrollment":2723,"conditions":2744,"interventions":2745},[64],[2725,1535],[2708,2727],{"trials":2747,"activeCount":73},[],{"trials":2749,"activeCount":73},[],{"intervention":2751,"totalTrials":109,"cells":2752},"fluocinolone acetonide",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2769,"NA":2771},{"trials":2754,"activeCount":73},[],{"trials":2756,"activeCount":73},[],{"trials":2758,"activeCount":73},[],{"trials":2760,"activeCount":73},[2761],{"nctId":2762,"briefTitle":2763,"status":85,"phases":2764,"primaryCompletion":2765,"completion":2765,"start":1133,"enrollment":2766,"conditions":2767,"interventions":2768},"NCT00502541","Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema",[63,64],"2006-09",196,[794],[2751],{"trials":2770,"activeCount":73},[],{"trials":2772,"activeCount":73},[],{"intervention":183,"totalTrials":1549,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2776,"activeCount":73},[],{"trials":2778,"activeCount":73},[],{"trials":2780,"activeCount":73},[2781,2788],{"nctId":2782,"briefTitle":2783,"status":175,"phases":2784,"primaryCompletion":2785,"completion":980,"start":2765,"enrollment":1259,"conditions":2786,"interventions":2787},"NCT00347646","A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)",[62,63],"2007-05",[181],[183],{"nctId":173,"briefTitle":174,"status":175,"phases":2789,"primaryCompletion":177,"completion":177,"start":178,"enrollment":179,"conditions":2790,"interventions":2791},[63],[181],[183,131],{"trials":2793,"activeCount":73},[],{"trials":2795,"activeCount":73},[],{"trials":2797,"activeCount":73},[],{"intervention":2799,"totalTrials":109,"cells":2800},"PF-03187207",{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2819,"PHASE4":2821,"NA":2823},{"trials":2802,"activeCount":73},[],{"trials":2804,"activeCount":73},[],{"trials":2806,"activeCount":73},[2807],{"nctId":2808,"briefTitle":2809,"status":85,"phases":2810,"primaryCompletion":613,"completion":613,"start":2811,"enrollment":2812,"conditions":2813,"interventions":2815},"NCT00595101","A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.",[63],"2007-12",117,[2814,31],"Primary Open Angle Glaucoma",[2799,2816,2817,2818],"Latanoprost 0.005%","PF-03187207 Vehicle","Latanoprost Vehicle",{"trials":2820,"activeCount":73},[],{"trials":2822,"activeCount":73},[],{"trials":2824,"activeCount":73},[],{"intervention":2816,"totalTrials":109,"cells":2826},{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2828,"activeCount":73},[],{"trials":2830,"activeCount":73},[],{"trials":2832,"activeCount":73},[2833],{"nctId":2808,"briefTitle":2809,"status":85,"phases":2834,"primaryCompletion":613,"completion":613,"start":2811,"enrollment":2812,"conditions":2835,"interventions":2836},[63],[2814,31],[2799,2816,2817,2818],{"trials":2838,"activeCount":73},[],{"trials":2840,"activeCount":73},[],{"trials":2842,"activeCount":73},[],{"intervention":2817,"totalTrials":109,"cells":2844},{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2849,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2846,"activeCount":73},[],{"trials":2848,"activeCount":73},[],{"trials":2850,"activeCount":73},[2851],{"nctId":2808,"briefTitle":2809,"status":85,"phases":2852,"primaryCompletion":613,"completion":613,"start":2811,"enrollment":2812,"conditions":2853,"interventions":2854},[63],[2814,31],[2799,2816,2817,2818],{"trials":2856,"activeCount":73},[],{"trials":2858,"activeCount":73},[],{"trials":2860,"activeCount":73},[],{"intervention":2818,"totalTrials":109,"cells":2862},{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2864,"activeCount":73},[],{"trials":2866,"activeCount":73},[],{"trials":2868,"activeCount":73},[2869],{"nctId":2808,"briefTitle":2809,"status":85,"phases":2870,"primaryCompletion":613,"completion":613,"start":2811,"enrollment":2812,"conditions":2871,"interventions":2872},[63],[2814,31],[2799,2816,2817,2818],{"trials":2874,"activeCount":73},[],{"trials":2876,"activeCount":73},[],{"trials":2878,"activeCount":73},[],{"intervention":2880,"totalTrials":109,"cells":2881},"0.3% BOL-303242-X ophthalmic suspension",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2883,"activeCount":73},[],{"trials":2885,"activeCount":73},[],{"trials":2887,"activeCount":73},[2888],{"nctId":2889,"briefTitle":2890,"status":85,"phases":2891,"primaryCompletion":257,"completion":1230,"start":269,"enrollment":2892,"conditions":2893,"interventions":2894},"NCT01163643","Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome",[63],356,[2179],[2880,2895,2896,2897,2898],"2% BOL-303242-X ophthalmic suspension","1% BOL-303242-X ophthalmic suspension","2% BOL-303242-X ophthalmic suspension AM","2% BOL-303242-X ophthalmic suspension PM",{"trials":2900,"activeCount":73},[],{"trials":2902,"activeCount":73},[],{"trials":2904,"activeCount":73},[],{"intervention":2895,"totalTrials":109,"cells":2906},{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2917,"PHASE4":2919,"NA":2921},{"trials":2908,"activeCount":73},[],{"trials":2910,"activeCount":73},[],{"trials":2912,"activeCount":73},[2913],{"nctId":2889,"briefTitle":2890,"status":85,"phases":2914,"primaryCompletion":257,"completion":1230,"start":269,"enrollment":2892,"conditions":2915,"interventions":2916},[63],[2179],[2880,2895,2896,2897,2898],{"trials":2918,"activeCount":73},[],{"trials":2920,"activeCount":73},[],{"trials":2922,"activeCount":73},[],{"intervention":2896,"totalTrials":109,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2926,"activeCount":73},[],{"trials":2928,"activeCount":73},[],{"trials":2930,"activeCount":73},[2931],{"nctId":2889,"briefTitle":2890,"status":85,"phases":2932,"primaryCompletion":257,"completion":1230,"start":269,"enrollment":2892,"conditions":2933,"interventions":2934},[63],[2179],[2880,2895,2896,2897,2898],{"trials":2936,"activeCount":73},[],{"trials":2938,"activeCount":73},[],{"trials":2940,"activeCount":73},[],{"intervention":2897,"totalTrials":109,"cells":2942},{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2944,"activeCount":73},[],{"trials":2946,"activeCount":73},[],{"trials":2948,"activeCount":73},[2949],{"nctId":2889,"briefTitle":2890,"status":85,"phases":2950,"primaryCompletion":257,"completion":1230,"start":269,"enrollment":2892,"conditions":2951,"interventions":2952},[63],[2179],[2880,2895,2896,2897,2898],{"trials":2954,"activeCount":73},[],{"trials":2956,"activeCount":73},[],{"trials":2958,"activeCount":73},[],{"intervention":2898,"totalTrials":109,"cells":2960},{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2962,"activeCount":73},[],{"trials":2964,"activeCount":73},[],{"trials":2966,"activeCount":73},[2967],{"nctId":2889,"briefTitle":2890,"status":85,"phases":2968,"primaryCompletion":257,"completion":1230,"start":269,"enrollment":2892,"conditions":2969,"interventions":2970},[63],[2179],[2880,2895,2896,2897,2898],{"trials":2972,"activeCount":73},[],{"trials":2974,"activeCount":73},[],{"trials":2976,"activeCount":73},[],{"intervention":2978,"totalTrials":109,"cells":2979},"Lotemax",{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2998,"PHASE4":3000,"NA":3002},{"trials":2981,"activeCount":73},[],{"trials":2983,"activeCount":73},[],{"trials":2985,"activeCount":73},[2986],{"nctId":2987,"briefTitle":2988,"status":85,"phases":2989,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":2992,"conditions":2993,"interventions":2995},"NCT01817582","Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)",[63],"2014-01-10","2013-05-17",102,[2994],"Keratoconjunctivitis Sicca",[2978,2996,2997],"Restasis","Soothe® Lubricant Eye Drops",{"trials":2999,"activeCount":73},[],{"trials":3001,"activeCount":73},[],{"trials":3003,"activeCount":73},[],{"intervention":2996,"totalTrials":109,"cells":3005},{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3016,"PHASE4":3018,"NA":3020},{"trials":3007,"activeCount":73},[],{"trials":3009,"activeCount":73},[],{"trials":3011,"activeCount":73},[3012],{"nctId":2987,"briefTitle":2988,"status":85,"phases":3013,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":2992,"conditions":3014,"interventions":3015},[63],[2994],[2978,2996,2997],{"trials":3017,"activeCount":73},[],{"trials":3019,"activeCount":73},[],{"trials":3021,"activeCount":73},[],{"intervention":2997,"totalTrials":109,"cells":3023},{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3028,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3025,"activeCount":73},[],{"trials":3027,"activeCount":73},[],{"trials":3029,"activeCount":73},[3030],{"nctId":2987,"briefTitle":2988,"status":85,"phases":3031,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":2992,"conditions":3032,"interventions":3033},[63],[2994],[2978,2996,2997],{"trials":3035,"activeCount":73},[],{"trials":3037,"activeCount":73},[],{"trials":3039,"activeCount":73},[],{"intervention":3041,"totalTrials":109,"cells":3042},"bromfenac ophthalmic solution 0.06%",{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3044,"activeCount":73},[],{"trials":3046,"activeCount":73},[],{"trials":3048,"activeCount":73},[3049],{"nctId":3050,"briefTitle":3051,"status":85,"phases":3052,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":3055,"conditions":3056,"interventions":3057},"NCT00758784","Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease",[63],"2009-01-14","2008-08-13",38,[157],[3041],{"trials":3059,"activeCount":73},[],{"trials":3061,"activeCount":73},[],{"trials":3063,"activeCount":73},[],{"intervention":3065,"totalTrials":109,"cells":3066},"Ketotifen\u002Fvasoconstrictor",{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3079,"PHASE4":3081,"NA":3083},{"trials":3068,"activeCount":73},[],{"trials":3070,"activeCount":73},[],{"trials":3072,"activeCount":73},[3073],{"nctId":3074,"briefTitle":3075,"status":712,"phases":3076,"enrollment":73,"conditions":3077,"interventions":3078},"NCT00375596","A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis",[63],[26],[3065],{"trials":3080,"activeCount":73},[],{"trials":3082,"activeCount":73},[],{"trials":3084,"activeCount":73},[],{"intervention":3086,"totalTrials":109,"cells":3087},"Ecabet",{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3100,"PHASE4":3102,"NA":3104},{"trials":3089,"activeCount":73},[],{"trials":3091,"activeCount":73},[],{"trials":3093,"activeCount":73},[3094],{"nctId":3095,"briefTitle":307,"status":85,"phases":3096,"primaryCompletion":980,"completion":980,"start":2765,"enrollment":3097,"conditions":3098,"interventions":3099},"NCT00370747",[63],162,[313],[3086,3086],{"trials":3101,"activeCount":73},[],{"trials":3103,"activeCount":73},[],{"trials":3105,"activeCount":73},[],{"intervention":3107,"totalTrials":109,"cells":3108},"BOL-303242-X",{"EARLY_PHASE1":3109,"PHASE1":3111,"PHASE2":3113,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3110,"activeCount":73},[],{"trials":3112,"activeCount":73},[],{"trials":3114,"activeCount":73},[3115],{"nctId":3116,"briefTitle":3117,"status":85,"phases":3118,"primaryCompletion":654,"completion":655,"start":353,"enrollment":3119,"conditions":3120,"interventions":3121},"NCT00905450","Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery",[63],415,[15,24],[3107,3122],"Vehicle for BOL-303242-X",{"trials":3124,"activeCount":73},[],{"trials":3126,"activeCount":73},[],{"trials":3128,"activeCount":73},[],{"intervention":3122,"totalTrials":109,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":73},[],{"trials":3134,"activeCount":73},[],{"trials":3136,"activeCount":73},[3137],{"nctId":3116,"briefTitle":3117,"status":85,"phases":3138,"primaryCompletion":654,"completion":655,"start":353,"enrollment":3119,"conditions":3139,"interventions":3140},[63],[15,24],[3107,3122],{"trials":3142,"activeCount":73},[],{"trials":3144,"activeCount":73},[],{"trials":3146,"activeCount":73},[],{"intervention":3148,"totalTrials":109,"cells":3149},"0.59 mg fluocinolone acetonide intravitreal implant",{"EARLY_PHASE1":3150,"PHASE1":3152,"PHASE2":3154,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3151,"activeCount":73},[],{"trials":3153,"activeCount":73},[],{"trials":3155,"activeCount":73},[3156],{"nctId":3157,"briefTitle":3158,"status":85,"phases":3159,"primaryCompletion":204,"completion":3160,"start":1134,"enrollment":766,"conditions":3161,"interventions":3162},"NCT00576459","Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema",[63],"2006-07",[794],[3148,3163],"2.1 mg fluocinolone acetonide intravitreal implant",{"trials":3165,"activeCount":73},[],{"trials":3167,"activeCount":73},[],{"trials":3169,"activeCount":73},[],{"intervention":3163,"totalTrials":109,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3182,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":73},[],{"trials":3175,"activeCount":73},[],{"trials":3177,"activeCount":73},[3178],{"nctId":3157,"briefTitle":3158,"status":85,"phases":3179,"primaryCompletion":204,"completion":3160,"start":1134,"enrollment":766,"conditions":3180,"interventions":3181},[63],[794],[3148,3163],{"trials":3183,"activeCount":73},[],{"trials":3185,"activeCount":73},[],{"trials":3187,"activeCount":73},[],{"intervention":3189,"totalTrials":109,"cells":3190},"PF-03187207 and Latanoprost Vehicle",{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3208,"PHASE4":3210,"NA":3212},{"trials":3192,"activeCount":73},[],{"trials":3194,"activeCount":73},[],{"trials":3196,"activeCount":73},[3197],{"nctId":3198,"briefTitle":3199,"status":85,"phases":3200,"primaryCompletion":3201,"completion":1210,"start":1240,"enrollment":3202,"conditions":3203,"interventions":3206},"NCT00441883","Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma",[63],"2008-02",176,[2814,31,3204,3205],"Pigmentary Glaucoma","Pseudoexfoliative Glaucoma",[3189,3207],"Latanoprost 0.005% and PF-03187207 Vehicle",{"trials":3209,"activeCount":73},[],{"trials":3211,"activeCount":73},[],{"trials":3213,"activeCount":73},[],{"intervention":3207,"totalTrials":109,"cells":3215},{"EARLY_PHASE1":3216,"PHASE1":3218,"PHASE2":3220,"PHASE3":3226,"PHASE4":3228,"NA":3230},{"trials":3217,"activeCount":73},[],{"trials":3219,"activeCount":73},[],{"trials":3221,"activeCount":73},[3222],{"nctId":3198,"briefTitle":3199,"status":85,"phases":3223,"primaryCompletion":3201,"completion":1210,"start":1240,"enrollment":3202,"conditions":3224,"interventions":3225},[63],[2814,31,3204,3205],[3189,3207],{"trials":3227,"activeCount":73},[],{"trials":3229,"activeCount":73},[],{"trials":3231,"activeCount":73},[],{"intervention":3233,"totalTrials":109,"cells":3234},"ecabet ophthalmic solution",{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3239,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3236,"activeCount":73},[],{"trials":3238,"activeCount":73},[],{"trials":3240,"activeCount":73},[3241],{"nctId":3242,"briefTitle":3243,"status":85,"phases":3244,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":3248,"interventions":3249},"NCT00667004","Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease",[63],"2008-09-12","2008-03-22",183,[157],[3233],{"trials":3251,"activeCount":73},[],{"trials":3253,"activeCount":73},[],{"trials":3255,"activeCount":73},[],{"intervention":3257,"totalTrials":109,"cells":3258},"bepotastine besilate ophthalmic solution",{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3273,"PHASE4":3275,"NA":3277},{"trials":3260,"activeCount":73},[],{"trials":3262,"activeCount":73},[],{"trials":3264,"activeCount":73},[3265],{"nctId":3266,"briefTitle":3267,"status":85,"phases":3268,"primaryCompletion":268,"completion":3269,"start":248,"enrollment":3270,"conditions":3271,"interventions":3272},"NCT01174823","Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients",[63],"2010-12",245,[26],[3257],{"trials":3274,"activeCount":73},[],{"trials":3276,"activeCount":73},[],{"trials":3278,"activeCount":73},[],{"intervention":3280,"totalTrials":109,"cells":3281},"Bepotastine besilate formulation",{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3298,"PHASE4":3300,"NA":3302},{"trials":3283,"activeCount":73},[],{"trials":3285,"activeCount":73},[],{"trials":3287,"activeCount":73},[3288],{"nctId":3289,"briefTitle":3290,"status":85,"phases":3291,"primaryCompletion":3292,"completion":3292,"start":246,"enrollment":3293,"conditions":3294,"interventions":3295},"NCT01578278","Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis",[63],"2012-08",606,[1853],[3280,3296,3297],"Fluticasone propionate","Bepotastine besilate-fluticasone propionate",{"trials":3299,"activeCount":73},[],{"trials":3301,"activeCount":73},[],{"trials":3303,"activeCount":73},[],{"intervention":3296,"totalTrials":109,"cells":3305},{"EARLY_PHASE1":3306,"PHASE1":3308,"PHASE2":3310,"PHASE3":3316,"PHASE4":3318,"NA":3320},{"trials":3307,"activeCount":73},[],{"trials":3309,"activeCount":73},[],{"trials":3311,"activeCount":73},[3312],{"nctId":3289,"briefTitle":3290,"status":85,"phases":3313,"primaryCompletion":3292,"completion":3292,"start":246,"enrollment":3293,"conditions":3314,"interventions":3315},[63],[1853],[3280,3296,3297],{"trials":3317,"activeCount":73},[],{"trials":3319,"activeCount":73},[],{"trials":3321,"activeCount":73},[],{"intervention":3297,"totalTrials":109,"cells":3323},{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3334,"PHASE4":3336,"NA":3338},{"trials":3325,"activeCount":73},[],{"trials":3327,"activeCount":73},[],{"trials":3329,"activeCount":73},[3330],{"nctId":3289,"briefTitle":3290,"status":85,"phases":3331,"primaryCompletion":3292,"completion":3292,"start":246,"enrollment":3293,"conditions":3332,"interventions":3333},[63],[1853],[3280,3296,3297],{"trials":3335,"activeCount":73},[],{"trials":3337,"activeCount":73},[],{"trials":3339,"activeCount":73},[],{"intervention":1277,"totalTrials":109,"cells":3341},{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3352,"PHASE4":3354,"NA":3356},{"trials":3343,"activeCount":73},[],{"trials":3345,"activeCount":73},[],{"trials":3347,"activeCount":73},[3348],{"nctId":1268,"briefTitle":1269,"status":85,"phases":3349,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":3350,"interventions":3351},[63],[691],[1258,1277],{"trials":3353,"activeCount":73},[],{"trials":3355,"activeCount":73},[],{"trials":3357,"activeCount":73},[],{"intervention":1372,"totalTrials":109,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3361,"activeCount":73},[],{"trials":3363,"activeCount":73},[],{"trials":3365,"activeCount":73},[3366],{"nctId":1366,"briefTitle":1367,"status":85,"phases":3367,"primaryCompletion":655,"completion":623,"start":288,"enrollment":1369,"conditions":3368,"interventions":3369},[63],[26],[1372,1372,1372,1373,1374],{"trials":3371,"activeCount":73},[],{"trials":3373,"activeCount":73},[],{"trials":3375,"activeCount":73},[],{"intervention":1373,"totalTrials":109,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3379,"activeCount":73},[],{"trials":3381,"activeCount":73},[],{"trials":3383,"activeCount":73},[3384],{"nctId":1366,"briefTitle":1367,"status":85,"phases":3385,"primaryCompletion":655,"completion":623,"start":288,"enrollment":1369,"conditions":3386,"interventions":3387},[63],[26],[1372,1372,1372,1373,1374],{"trials":3389,"activeCount":73},[],{"trials":3391,"activeCount":73},[],{"trials":3393,"activeCount":73},[],{"intervention":3395,"totalTrials":109,"cells":3396},"bepotastine besilate nasal product - low dose",{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3398,"activeCount":73},[],{"trials":3400,"activeCount":73},[],{"trials":3402,"activeCount":73},[3403],{"nctId":3404,"briefTitle":3405,"status":85,"phases":3406,"primaryCompletion":623,"completion":623,"start":655,"enrollment":3407,"conditions":3408,"interventions":3409},"NCT01222299","Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber",[62,63],89,[1853],[3395,3410,3411],"bepotastine besilate nasal product - medium dose","bepotastine besilate nasal product - high dose",{"trials":3413,"activeCount":73},[],{"trials":3415,"activeCount":73},[],{"trials":3417,"activeCount":73},[],{"intervention":3410,"totalTrials":109,"cells":3419},{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3421,"activeCount":73},[],{"trials":3423,"activeCount":73},[],{"trials":3425,"activeCount":73},[3426],{"nctId":3404,"briefTitle":3405,"status":85,"phases":3427,"primaryCompletion":623,"completion":623,"start":655,"enrollment":3407,"conditions":3428,"interventions":3429},[62,63],[1853],[3395,3410,3411],{"trials":3431,"activeCount":73},[],{"trials":3433,"activeCount":73},[],{"trials":3435,"activeCount":73},[],{"intervention":3411,"totalTrials":109,"cells":3437},{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3439,"activeCount":73},[],{"trials":3441,"activeCount":73},[],{"trials":3443,"activeCount":73},[3444],{"nctId":3404,"briefTitle":3405,"status":85,"phases":3445,"primaryCompletion":623,"completion":623,"start":655,"enrollment":3407,"conditions":3446,"interventions":3447},[62,63],[1853],[3395,3410,3411],{"trials":3449,"activeCount":73},[],{"trials":3451,"activeCount":73},[],{"trials":3453,"activeCount":73},[],{"intervention":1383,"totalTrials":109,"cells":3455},{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3466,"PHASE4":3468,"NA":3470},{"trials":3457,"activeCount":73},[],{"trials":3459,"activeCount":73},[],{"trials":3461,"activeCount":73},[3462],{"nctId":1376,"briefTitle":1377,"status":85,"phases":3463,"primaryCompletion":1379,"completion":1379,"start":1380,"enrollment":1327,"conditions":3464,"interventions":3465},[63],[34],[1383,1383,1384],{"trials":3467,"activeCount":73},[],{"trials":3469,"activeCount":73},[],{"trials":3471,"activeCount":73},[],{"intervention":3473,"totalTrials":109,"cells":3474},"WB007 0.05%",{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3479,"PHASE3":3494,"PHASE4":3496,"NA":3498},{"trials":3476,"activeCount":73},[],{"trials":3478,"activeCount":73},[],{"trials":3480,"activeCount":73},[3481],{"nctId":3482,"briefTitle":3483,"status":85,"phases":3484,"primaryCompletion":3485,"completion":3486,"start":788,"enrollment":3487,"conditions":3488,"interventions":3490},"NCT04149899","Safety and IOP-Lowering Effects of WB007",[62,63],"2021-01-31","2022-12-14",77,[3489,31],"Glaucoma, Primary Open Angle",[3473,3491,3492,3493],"WB007 0.15%","WB007 0.4%","Timolol 0.5%",{"trials":3495,"activeCount":73},[],{"trials":3497,"activeCount":73},[],{"trials":3499,"activeCount":73},[],{"intervention":3491,"totalTrials":109,"cells":3501},{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3512,"PHASE4":3514,"NA":3516},{"trials":3503,"activeCount":73},[],{"trials":3505,"activeCount":73},[],{"trials":3507,"activeCount":73},[3508],{"nctId":3482,"briefTitle":3483,"status":85,"phases":3509,"primaryCompletion":3485,"completion":3486,"start":788,"enrollment":3487,"conditions":3510,"interventions":3511},[62,63],[3489,31],[3473,3491,3492,3493],{"trials":3513,"activeCount":73},[],{"trials":3515,"activeCount":73},[],{"trials":3517,"activeCount":73},[],{"intervention":3492,"totalTrials":109,"cells":3519},{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3530,"PHASE4":3532,"NA":3534},{"trials":3521,"activeCount":73},[],{"trials":3523,"activeCount":73},[],{"trials":3525,"activeCount":73},[3526],{"nctId":3482,"briefTitle":3483,"status":85,"phases":3527,"primaryCompletion":3485,"completion":3486,"start":788,"enrollment":3487,"conditions":3528,"interventions":3529},[62,63],[3489,31],[3473,3491,3492,3493],{"trials":3531,"activeCount":73},[],{"trials":3533,"activeCount":73},[],{"trials":3535,"activeCount":73},[],{"intervention":3493,"totalTrials":109,"cells":3537},{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3548,"PHASE4":3550,"NA":3552},{"trials":3539,"activeCount":73},[],{"trials":3541,"activeCount":73},[],{"trials":3543,"activeCount":73},[3544],{"nctId":3482,"briefTitle":3483,"status":85,"phases":3545,"primaryCompletion":3485,"completion":3486,"start":788,"enrollment":3487,"conditions":3546,"interventions":3547},[62,63],[3489,31],[3473,3491,3492,3493],{"trials":3549,"activeCount":73},[],{"trials":3551,"activeCount":73},[],{"trials":3553,"activeCount":73},[],{"intervention":1288,"totalTrials":109,"cells":3555},{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3557,"activeCount":73},[],{"trials":3559,"activeCount":73},[],{"trials":3561,"activeCount":73},[3562],{"nctId":1279,"briefTitle":1280,"status":85,"phases":3563,"primaryCompletion":226,"completion":1282,"start":1283,"enrollment":1284,"conditions":3564,"interventions":3565},[63],[31,1286],[1258,1288],{"trials":3567,"activeCount":73},[],{"trials":3569,"activeCount":73},[],{"trials":3571,"activeCount":73},[],{"intervention":3573,"totalTrials":109,"cells":3574},"Bepotastine Besilate Nasal Spray 2% Twice a day",{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3590,"PHASE4":3592,"NA":3594},{"trials":3576,"activeCount":73},[],{"trials":3578,"activeCount":73},[],{"trials":3580,"activeCount":73},[3581],{"nctId":3582,"briefTitle":3583,"status":85,"phases":3584,"primaryCompletion":166,"completion":1231,"start":3269,"enrollment":3585,"conditions":3586,"interventions":3587},"NCT01277341","Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis",[63],601,[1853],[3573,3588,3589],"Bepotastine Besilate Nasal Spray 3% Twice a day","Bepotastine Besilate Nasal Spray 4% Twice a day",{"trials":3591,"activeCount":73},[],{"trials":3593,"activeCount":73},[],{"trials":3595,"activeCount":73},[],{"intervention":3588,"totalTrials":109,"cells":3597},{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3599,"activeCount":73},[],{"trials":3601,"activeCount":73},[],{"trials":3603,"activeCount":73},[3604],{"nctId":3582,"briefTitle":3583,"status":85,"phases":3605,"primaryCompletion":166,"completion":1231,"start":3269,"enrollment":3585,"conditions":3606,"interventions":3607},[63],[1853],[3573,3588,3589],{"trials":3609,"activeCount":73},[],{"trials":3611,"activeCount":73},[],{"trials":3613,"activeCount":73},[],{"intervention":3589,"totalTrials":109,"cells":3615},{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3617,"activeCount":73},[],{"trials":3619,"activeCount":73},[],{"trials":3621,"activeCount":73},[3622],{"nctId":3582,"briefTitle":3583,"status":85,"phases":3623,"primaryCompletion":166,"completion":1231,"start":3269,"enrollment":3585,"conditions":3624,"interventions":3625},[63],[1853],[3573,3588,3589],{"trials":3627,"activeCount":73},[],{"trials":3629,"activeCount":73},[],{"trials":3631,"activeCount":73},[],{"intervention":3633,"totalTrials":109,"cells":3634},"Part 2 group 2",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3650,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3636,"activeCount":73},[],{"trials":3638,"activeCount":73},[3639],{"nctId":3640,"briefTitle":3641,"status":85,"phases":3642,"primaryCompletion":3643,"completion":3644,"start":3645,"enrollment":3646,"conditions":3647,"interventions":3649},"NCT03282929","Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)",[62],"2018-09-28","2018-10-15","2017-03-23",43,[3648],"Anaphylaxis",[3633],{"trials":3651,"activeCount":73},[],{"trials":3653,"activeCount":73},[],{"trials":3655,"activeCount":73},[],{"trials":3657,"activeCount":73},[],{"intervention":3659,"totalTrials":109,"cells":3660},"LE Gel",{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3673,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3662,"activeCount":73},[],{"trials":3664,"activeCount":73},[3665],{"nctId":3666,"briefTitle":3667,"status":85,"phases":3668,"primaryCompletion":1308,"completion":3669,"start":1308,"enrollment":8,"conditions":3670,"interventions":3672},"NCT01736527","Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation",[62],"2013-04",[3671],"Pharmacokinetics",[3659],{"trials":3674,"activeCount":73},[],{"trials":3676,"activeCount":73},[],{"trials":3678,"activeCount":73},[],{"trials":3680,"activeCount":73},[],{"intervention":3682,"totalTrials":109,"cells":3683},"Besifloxacin Ophthalmic Suspension 0.6%",{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3700},{"trials":3685,"activeCount":73},[],{"trials":3687,"activeCount":73},[3688],{"nctId":3689,"briefTitle":3690,"status":85,"phases":3691,"primaryCompletion":1211,"completion":3201,"start":2785,"enrollment":1026,"conditions":3692,"interventions":3693},"NCT01120418","Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days",[62],[602],[3682],{"trials":3695,"activeCount":73},[],{"trials":3697,"activeCount":73},[],{"trials":3699,"activeCount":73},[],{"trials":3701,"activeCount":73},[],{"intervention":3703,"totalTrials":109,"cells":3704},"BOL-303224-A",{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3723},{"trials":3706,"activeCount":73},[],{"trials":3708,"activeCount":73},[3709],{"nctId":3710,"briefTitle":3711,"status":85,"phases":3712,"primaryCompletion":1211,"completion":1211,"start":3713,"enrollment":556,"conditions":3714,"interventions":3716},"NCT00407589","Systemic Pharmacokinetics of BOL-303224-A",[62],"2006-10",[3715],"Conjunctivitis, Bacterial",[3703],{"trials":3718,"activeCount":73},[],{"trials":3720,"activeCount":73},[],{"trials":3722,"activeCount":73},[],{"trials":3724,"activeCount":73},[],{"intervention":1331,"totalTrials":109,"cells":3726},{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3735,"PHASE3":3737,"PHASE4":3739,"NA":3741},{"trials":3728,"activeCount":73},[],{"trials":3730,"activeCount":73},[3731],{"nctId":1322,"briefTitle":1323,"status":85,"phases":3732,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":3733,"interventions":3734},[62],[602],[1330,1331,219],{"trials":3736,"activeCount":73},[],{"trials":3738,"activeCount":73},[],{"trials":3740,"activeCount":73},[],{"trials":3742,"activeCount":73},[],{"intervention":1493,"totalTrials":109,"cells":3744},{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3753,"PHASE3":3755,"PHASE4":3757,"NA":3759},{"trials":3746,"activeCount":73},[],{"trials":3748,"activeCount":73},[3749],{"nctId":1484,"briefTitle":1485,"status":85,"phases":3750,"primaryCompletion":1487,"completion":1488,"start":1249,"enrollment":1489,"conditions":3751,"interventions":3752},[62],[1491],[1493,1494,1495],{"trials":3754,"activeCount":73},[],{"trials":3756,"activeCount":73},[],{"trials":3758,"activeCount":73},[],{"trials":3760,"activeCount":73},[],{"intervention":1494,"totalTrials":109,"cells":3762},{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3771,"PHASE3":3773,"PHASE4":3775,"NA":3777},{"trials":3764,"activeCount":73},[],{"trials":3766,"activeCount":73},[3767],{"nctId":1484,"briefTitle":1485,"status":85,"phases":3768,"primaryCompletion":1487,"completion":1488,"start":1249,"enrollment":1489,"conditions":3769,"interventions":3770},[62],[1491],[1493,1494,1495],{"trials":3772,"activeCount":73},[],{"trials":3774,"activeCount":73},[],{"trials":3776,"activeCount":73},[],{"trials":3778,"activeCount":73},[],{"intervention":1753,"totalTrials":69,"cells":3780},{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3787,"PHASE4":3797,"NA":3799},{"trials":3782,"activeCount":73},[],{"trials":3784,"activeCount":73},[],{"trials":3786,"activeCount":73},[],{"trials":3788,"activeCount":73},[3789,3793],{"nctId":1744,"briefTitle":1745,"status":85,"phases":3790,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":1749,"conditions":3791,"interventions":3792},[63,64],[1751],[1753,1754],{"nctId":2433,"briefTitle":2434,"status":85,"phases":3794,"primaryCompletion":204,"completion":204,"start":2436,"enrollment":670,"conditions":3795,"interventions":3796},[63,64],[1740],[1753,2422],{"trials":3798,"activeCount":73},[],{"trials":3800,"activeCount":73},[3801],{"nctId":3802,"briefTitle":3803,"status":85,"phases":3804,"primaryCompletion":3805,"completion":3806,"start":3807,"enrollment":69,"conditions":3808,"interventions":3810},"NCT03145025","Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant",[],"2018-09-10","2019-03-22","2017-07-14",[3809],"Uveitis, Posterior",[3811],"Fluocinolone Acetonide Intravitreal Implant",{"intervention":3813,"totalTrials":109,"cells":3814},"ISTA Tears",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3821,"PHASE4":3823,"NA":3825},{"trials":3816,"activeCount":73},[],{"trials":3818,"activeCount":73},[],{"trials":3820,"activeCount":73},[],{"trials":3822,"activeCount":73},[],{"trials":3824,"activeCount":73},[],{"trials":3826,"activeCount":73},[3827],{"nctId":3828,"briefTitle":3829,"status":85,"phases":3830,"primaryCompletion":3831,"completion":1308,"start":3832,"enrollment":3833,"conditions":3834,"interventions":3835},"NCT01650584","Evaluation of Ocular Comfort With ISTA Tears vs Systane",[66],"2012-12","2012-06",35,[157],[3813,3836],"Systane",{"intervention":3836,"totalTrials":109,"cells":3838},{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3845,"PHASE4":3847,"NA":3849},{"trials":3840,"activeCount":73},[],{"trials":3842,"activeCount":73},[],{"trials":3844,"activeCount":73},[],{"trials":3846,"activeCount":73},[],{"trials":3848,"activeCount":73},[],{"trials":3850,"activeCount":73},[3851],{"nctId":3828,"briefTitle":3829,"status":85,"phases":3852,"primaryCompletion":3831,"completion":1308,"start":3832,"enrollment":3833,"conditions":3853,"interventions":3854},[66],[157],[3813,3836]]